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Abstract 
The World Health Organization (WHO) states that 30,000 children under the 
age of five die each day worldwide. Around a quarter of these die from 
diarrheal disease caused by microbial infection. In addition to this high 
mortality rate, there are data emerging on the morbidity effects of diarrheal 
disease, for example a few episodes of diarrhea in the first two years of life 
can remove 10 IQ points and lead to growth deficiency. Vibrio cholerae, the 
causative agent of the diarrheal disease cholera, is a serious problem in third 
world countries, where sanitary and hygiene infrastructure is very poor, and 
claims several thousand lives every year. In order to better understand the 
pathogenicity regulation in V. cholerae, structural and functional investigations 
of a hypothetical protein family present in pathogenicity islands and a 
transcriptional regulator protein for DNA-binding were investigated. 
Two adjacent genes, vc1804 and vc1805, encode hypothetical proteins within 
the Vibrio pathogenicity island-2 (VPI-2) of Vibrio cholerae, and are part of a 
cluster of genes only present in pathogenic strains of the bacterium. 
Paralogous adjacent genes, vc0508 and vc0509, are also present within a 
second pathogenicity island, the Vibrio seventh pandemic island-2 (VSP-2), of 
V. cholerae O1 El Tor and O139 serogroup isolates. Sequence similarity 
suggests that the VC0508, VC0509, VC1804 and VC1805 proteins will share 
a similar fold. The crystal structures of VC0508, VC0509 and VC1805 have 
been determined to a resolution of 1.9, 2.4 and 2.1 Å, respectively. Several 
recombinant constructs of vc1804 were made, but no soluble proteins were 
expressed. This hypothetical protein family reveals structural homology to 
 xiii 
human mitochondrial protein p32. Human p32 is a promiscuous protein known 
to bind to a variety of partners including the globular head component of C1q. 
We have shown that VC1805 binds to C1q. One possibility is that VC1805 is 
involved in adherence of the bacterium to membrane-bound C1q in the gut. 
To explore the roles of VC0508, VC0509, VC1804 and VC1805 in vivo, gene 
knockout and animal model studies of those proteins are underway. 
The ferric uptake regulator (Fur), a metal-dependent DNA-binding protein, 
acts as both a repressor and activator of numerous genes involved in 
maintaining iron homeostasis in bacteria. It has also been demonstrated in 
Vibrio cholerae that Fur plays an additional role in pathogenesis, and this 
opens up the potential of Fur as a drug target for cholera. The first crystal 
structure of a Fur protein, from Pseudomonas aeruginosa, revealed a dimeric 
molecule with each monomer containing a dimerization domain, a helical 
DNA-binding domain and two metal binding sites: Zn1 is proposed to be a 
regulatory Fe-binding site, and Zn2 is proposed to be a structural Zn-binding 
site. Here we present the crystal structure of V. cholerae Fur (VcFur) that 
reveals a very different orientation of the DNA-binding domains. 
Accompanying these structural changes are alterations in the amino acids 
coordinating the zinc at the Zn2 site, and this lends support to this being the 
site regulated by iron. There is no evidence of metal binding to the cysteines 
that are conserved in many Fur homologues, including the much-studied 
E. coli Fur. An analysis of the metal binding properties shows that like other 
Fur proteins, VcFur can be activated by a range of divalent metals. EPR 
spectroscopy measurements of the movements of the DNA-binding domain, 
in the presence of DNA and different metals, are underway. 
 xiv 
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 2 
1. Introduction 
1.1 Overview of cholera 
The severe diarrhoeal disease cholera is caused by the Gram-negative 
bacterium Vibrio cholerae (Figure 1.1) and continues to be a major cause of 
morbidity and mortality. Annually, cholera causes the death of more than a 
hundred thousand people among millions of reported cases worldwide 
(Faruque et al., 1998a). V. cholerae was identified as the causative agent of 
cholera in 1884 during the fifth pandemic. The isolation of a bacteria capable 
of producing a toxin that stimulated massive loss of fluid from the intestine 
were reported (DiRita, 2001). But the cause of cholera associated with the 
contaminated water was determined in 1854 by an epidemiologist John Snow 
in London (Snow et al., 1936). V. cholerae has more than 200 known 
serotypes but not all the strains are pathogenic. Among them, only those 
strains with O1 and O139 antigens are highly pathogenic and acknowledged 
to cause epidemic and pandemic disease (Reidl and Klose, 2002). Strains of 
V. cholerae which do not agglutinate with O1 or O139 antisera are called non-
O1 or non-O139 V. cholerae respectively and are not thought to be involved in 
epidemic cholera. However, these non-epidemic strains could be pathogenic 
(Morris et al., 1990) as they are occasionally associated with small outbreaks 
of diarrheal disease (Aldova et al., 1968). V. cholerae O1 and O139 typically 
cause intermittent outbreaks of diarrhoeal disease and rarely cause extra 
intestinal infection, but V. cholerae non-O1, non-O139 and other Vibrio 
species may cause frequent bacteremia in immunocompromised individuals 
(Ko et al., 1998; Safrin et al., 1988). 
 3 
The main source of cholera is contaminated water and food (ICDDRB, 1993). 
The infective dose for V. cholerae is 106 cells. However the ultimate infection 
depends on some other factors, for instance, personal immunity, the gastric-
acid barrier and overall sanitary conditions (Sack et al., 2004). Even more 
interestingly, people with blood group O are highly susceptible to V. cholerae 
El Tor strain infection compared to others (Barua and Paguio, 1977; Clemens 
et al., 1989; Glass et al., 1985).  
The characteristic symptom of the acute form of cholera is rice water stools. 
Clinical manifestations of the disease range from mild symptoms such as 
abdominal cramps, nausea and vomiting, to more severe symptoms such as 
dehydration, shock and death (Weir and Haider, 2004). In case of severe 
cholera, the rate of fluid loss from the body could reach 500-1000 mL/h that 
can cause dangerous dehydration (Sack et al., 2004). Additionally, 
inappropriate treatment can lead to further complications such as acute renal 
failure due to insufficient fluid administration to the patient or severe 
hypoglycemia resulting from low blood glucose concentrations (Butler et al., 
1989). If the infection is severe and the patient left untreated, an adult could 
die within 24 h (Schoolnik and Yildiz, 2000). 
Over a century of research, knowledge about cholera has increased a lot, but 
the ultimate solution to the problem has not yet been found, as it is still 
devastating and can spread very rapidly in third-world countries where the 
degree of the disease is fatal. 
 4 
 
Figure 1.1 A 10,000 times magnification of V. cholerae bacterium (Waldor 
and RayChaudhuri, 2000). 
1.2 Cholera: History of global pain  
According to the recent reports in various international media in February 
2009, the outbreak of cholera in Zimbabwe has already killed 3800 people, 
since the outbreak started in August 2008. Approximately 60,000 cases have 
been reported with a mortality rate of about 5%, according to United Nations 
and World Health Organization (WHO). Now this cholera outbreak is 
spreading to other neighbouring countries like South Africa where 36 people 
have already been killed among 5,696 reported cases and most of the 
affected regions are near Zimbabwean borders (Kapp, 2009). 
The fearsome reputation of cholera as a disease has arisen due to its 
frequent occurrence in epidemic proportion coupled to its high mortality rates 
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(Sack et al., 2004). Every year cholera causes illness in millions of individuals 
including children who are highly susceptible (WHO, 1995). The first recorded 
cholera pandemic began in 1817. The infection rapidly spread from the Indian 
sub-continent along trade routes as far as southern Russia. A second 
pandemic, starting in 1826 leading to the third, fourth and fifth pandemics 
persisting until the 19th century, wrought havoc in Asia, Africa, Europe and the 
Americas (Pollitzer, 1954). The sixth pandemic, started in 1899 and persisted 
until 1923, spreading extensively in the Middle-East and Balkan regions 
(Pollitzer, 1959). 
 
 
 
 
 
 
 
Figure 1.2 The seventh cholera pandemic (Institute of Tropical Medicine in 
Antwerp, Belgium). 
In the Indian sub-continent, cholera epidemics emerge with alarming 
frequency and are usually initiated in the Ganges Delta region. These 
epidemics often spread to other continents over the course of many years 
claiming thousands of lives on their way (Pollitzer, 1954). Only the seventh 
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pandemic arose outside the Indian sub-continent, beginning in 1961 on the 
Island of Sulawesi in Indonesia before spreading to other countries. This 
pandemic is the most extensive with regard to geographic spread and 
duration, and the causative agent is V. cholerae O1 biotype E1 Tor 
(Cvjetanovic and Barua, 1972). The strain was named after the village El Tor 
in Egypt where it was first isolated in 1905 (Pollitzer, 1959). Later, it appeared 
in 1937 in Sulawesi, Indonesia (Tanamal, 1959). The strain began to spread 
all over the world in 1961 causing the seventh pandemic. The seventh 
pandemic continues to ravage parts of the world today, shown in Figure 1.2, 
with particularly devastating effect in developing countries such as India, 
Bangladesh, Rwanda and Mozambique (Sack et al., 2004). 
V. cholerae serogroup O1 is classified into two biotypes, which are termed 
‘classical’ and ‘El Tor’. The current pandemic of cholera is caused by the El 
Tor biotype, but the fifth and sixth pandemics of cholera were caused by the 
classical biotype. The classical biotype of V. cholerae O1 is thought to have 
become extinct with the El Tor biotype becoming the dominant biotype. 
Indeed, the classical biotype has not featured in epidemic cholera outbreaks 
since 1983 (Samadi et al., 1983). Another serogroup called V. cholerae O139 
was first discovered in 1992 when it caused severe outbreaks in India and 
Bangladesh (ICDDRB, 1993; Ramamurthy et al., 1993). There was another 
outbreak associated with O139 serotype where 30,000 people were infected 
in Dhaka, which surpassed the number of cases associated with seventh 
pandemic El Tor strain (Faruque et al., 2003a). It has been debated whether 
this serogroup may herald the beginning of an eighth cholera pandemic 
(Swerdlow and Ries, 1993). 
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1.3 Ecology of Vibrio cholerae 
After the discovery of the V. cholerae bacteria in 1884 by Robert Koch, the 
first assumption was that an aquatic environment acted as the reservoir for 
vibrios. Koch isolated comma bacillus from a tank in Calcutta during the 
cholera epidemic in 1883 (DiRita, 2001). V. cholerae was isolated from areas 
free from fecal pollution and it was proposed that the bacterium belongs to the 
bacterial flora populating brackish water and estuarine systems and the 
phenomenon of aquatic environment as the natural reservoir of V. cholerae 
was established (Colwell et al., 1977). During an investigation to test the 
viability of V. cholerae, it was reported that the V. cholerae bacterium was 
able to survive in a number of different natural water sources over a period of 
time ranging from 1-6 days (Lahiri et al., 1939). Indeed, V. cholerae has the 
ability to survive up to 1 month at 4°C and 2 to 14 days at 20°C to 30°C in 
dechlorinated clean water (Feachem et al., 1981). 
V. cholerae can survive in association with aquatic flora such as 
phytoplankton as well as zooplankton, particularly on copepods (Islam et al., 
1994; Samadi et al., 1983). It has also been reported that V. cholerae can 
attach to the blue green algae Anabaena variabilis for up to 5 days within the 
algae’s natural habitat. In addition, the bacterium does not lose its ability to 
produce the cholera toxin following its association with the algae. This study 
also suggested that A. variabilis has the ability to act as a reservoir of 
V. cholerae O1 in the aquatic environment (Islam et al., 1990; Islam et al., 
1993, 1994). The association of V. cholerae strains with zooplankton and 
phytoplankton are well established and could also interfere with global climate 
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change by affecting the growth of planktons (Sack et al., 2004). In the 
absence of disease, the presence of pathogenic V. cholerae O1 in aquatic 
environments indicates both the tenacity of the organism and its ability to 
flourish within a natural environment (Colwell et al., 1981). 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Figure 1.3 Life cycles of V. cholerae (Sack et al., 2004) 
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There are two distinctive life cycles for V. cholerae that occur inside the host 
(human) and outside the host (environment). These cycles, shown in 
Figure 1.3, involve different intermediate steps that sometimes intersect (Sack 
et al., 2004). Isolated pathogenic strains of V. cholerae from infected areas 
possess cholera toxin (CT) genes whereas the similar isolates from 
uninfected areas do not possess CT (Faruque et al., 1998b). 
1.4 Evolution of Vibrio cholerae 
V. cholerae had long been part of the environment before it became 
pathogenic. Most of the strains of V. cholerae are still part of the natural flora 
(Colwell and Spira, 1992). Pathogenic strains of V. cholerae contain a few 
chromosomal regions, acquired by horizontal gene transfer, which are absent 
in non-pathogenic strains, and are vital for the evolution of pathogenic strains 
(Faruque and Mekalanos, 2003). For example, V. cholerae have an 
extraordinary survival mechanism, as they can uptake new genetic material 
while they grow on chitin, an abundant natural habitat of V. cholerae (Meibom 
et al., 2005). Addition and deletion of some chromosomal regions between 
pathogenic strains assists the emergence of new classes of pathogenic 
clones. For example, the evolution of V. cholerae O139 epidemic strain 
occurred as a result of horizontal gene transfer events which deleted or 
replaced a few genes encoding the enzyme for the synthesis of 
lipopolysaccharide (LPS) O-antigen side chain (Bik et al., 1995; Waldor et al., 
1994). The relationship between the evolution of pathogenic strains of 
V. cholerae and the ability of the organism to survive in the environment is not 
very clear, as some of the environmental strains are pathogenic but are not 
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involved in epidemic patterns of cholera (Boyd and Waldor, 2002; Faruque et 
al., 2003b). The possible evolutionary linages of V. cholerae pathogenic 
strains are shown in Figure 1.4 (Faruque and Mekalanos, 2003). 
 
 
 
 
 
 
 
 
 
Figure 1.4 Evolution of the possible pathogenic strains of V. cholerae 
(Faruque and Mekalanos, 2003). The strains that have been reported are in 
shaded boxes and the white boxes represent possible strains yet to be 
discovered. Evolution of strains by horizontal gene transfer events are 
indicated by purple arrows whereas the red arrows indicate other transfer 
events that could be possible but the intermediate strains of these events 
have not been isolated yet. Abbreviations: EPS, extracellular protein secretion 
gene cluster; HAP, hemagglutinin protease gene. 
1.5 Genome sequence of Vibrio cholera: inside of the killer  
The V. cholerae strains consist of two separate chromosomes. The smaller 
chromosome is predicted to be a megaplasmid which became an essential 
part during the evolutionary process after gaining some essential genes (Egan 
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et al., 2005; Heidelberg et al., 2000). In the year 2000, the sequencing of the 
V. cholerae O1 El Tor genome started to reveal the significance of the 
pathogenicity of the organism. V. cholerae has two circular chromosomes of 
2,961,151 bp and 1,072,914 bp, named as chromosome-I and chromosome-II 
and encode 2,770 and 1,115 open reading frames (ORFs), respectively 
(Figure 1.5). The larger chromosome encodes 19% hypothetical proteins and 
17% conserved hypothetical proteins whereas the smaller chromosome 
encodes 38% hypothetical genes and 15% conserved hypothetical proteins. 
Most of the essential genes including pathogenicity island genes of 
V. cholerae are present in chromosome-I (Heidelberg et al., 2000). 
 
 
 
 
 
 
Figure 1.5 V. cholerae genome map. Circular representation of large (right) 
and small (left) chromosome. The outermost rings (circles 1 and 2) show 
predicted protein-coding regions (hypothetical proteins are in black). The third 
circle shows recently duplicated genes. The fourth circle shows transposon-
related (black), phage-related (blue), V. cholerae repeat sequence (pink) and 
pathogenesis genes (red). The fifth circle shows χ2 values for trinucleotide 
composition. The sixth circle shows G+C percentage. The seventh and eighth 
circles are tRNAs and rRNAs, respectively (Heidelberg et al., 2000). 
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1.6 Molecular basis of Vibrio cholerae pathogenesis 
The molecular basis of V. cholerae pathogenesis is a complex process that 
has not been fully understood. It involves expression of numerous virulence 
genes which primarily helps the bacterium to pass the gastric acid barrier in 
order to colonize the small intestine, resulting in the secretion of cholera toxin 
(CT) (Kaper et al., 1995). Upon colonization of the mucosa of the small 
intestine, V. cholerae secretes CT as a major virulence factor. CT is a protein-
protein complex made up of six separate subunits: a single copy of the 
globular A (29 kDa) subunit, and five copies of the B subunit. The five 
identical 11 kDa B subunits ally to form a pentameric ring-like structure that 
then assembles in a non-covalent fashion with the A subunit. The A subunit 
includes two sub-segments which are linked to each other via a disulphide 
bond (Sixma et al., 1991; Zhang et al., 1995). 
Upon secretion of CT, the B subunit ring binds to GM1 gangliosides on the 
surface of host cells. After binding has occurred, the cell internalizes the entire 
CT complex and the CTA1 (23.5 kDa) chain is released via reduction of a 
disulfide bridge. CTA1 is then free to bind with a human partner protein called 
ADP-ribosylation factor 6 (Arf6). Binding to Arf6 induces a conformational 
change upon CTA1 exposing its active site and enabling catalytic activity. The 
CTA1 fragment catalyses ADP ribosylation from NAD to the regulatory 
component of adenylate cyclase resulting in increase of adenylate cyclase 
activity followed by increase of cyclic AMP (cAMP) synthesis. The presence of 
a higher concentration of cAMP pumps large amounts of chloride ion (Cl-) 
from toxin damaged mucosal cells to the intestine. Consequently, water, Na+ 
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and other electrolytes are also pumped out due to the imbalanced osmotic 
and electrical gradients caused by the loss of Cl-. The loss of water and 
electrolytes from the toxin damaged mucosal cells to intestine leads to 
characteristic symptoms of cholera (DiRita, 2001; O'Neal et al., 2005; Zhang 
et al., 1995). A schematic diagram of the cholera toxin activation mechanism 
is shown in Figure 1.6. 
 
 
 
 
 
 
 
 
 
 
Figure 1.6 Mechanism of activation of cholera enterotoxin 
(http://gsbs.utmb.edu/microbook/ch024.htm). 
1.7 Virulence factors of Vibrio cholerae 
The pathogenesis of cholera depends on several factors that act in 
combination to assist the bacterium to colonize the gastrointestinal tract. 
During colonization in the epithelium of the small intestine, pathogenic strains 
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of V. cholerae produce CT that interrupts ion transport by epithelial cells and 
causes diarrhoea. Even though the manifestations of diarrhoea are 
associated with the production of CT, the pathogenesis of cholera depends on 
the synergistic action of several proteins (Kaper et al., 1995). The 
pathogenicity of V. cholerae involves a number of important genetic elements 
that act to distinguish them from non-pathogenic strains. 
1.7.1 CTX (cholera toxin phage) genetic element  
By horizontal gene transfer, the CTXΦ genome can integrate into the 
V. cholerae genome, or alternatively, the phage itself can stay as a plasmid 
inside V. cholerae due to the lack of an appropriate integration site, and can 
replicate during cell division. CTX genetic element is a chromosomally 
integrated CTXΦ genome that carries the gene ctxAB encoding CT. All 
epidemic V. cholerae isolates contain CTXΦ but it is rarely recovered from 
non-O1/non-O139 V. cholerae environmental isolates (Faruque et al., 1998a). 
The CTXΦ has a 6.9 kb genome consisting of two functionally diverse regions 
(Figure 1.7). The ‘core region’ that carries the ctxAB operon encodes CT as 
well as genes essential for phage morphogenesis which are thought to 
encode the major and minor phage coat proteins and a protein required for 
CTXΦ assembly (Table 1.1). The RS2 region consists of genes that encode 
products required for the integration, replication and regulatory functions of 
CTXΦ. The CTXΦ is frequently flanked by an additional region, named RS1 
(Figure 1.7 and Table 1.1). RS1 is 2.7 kb in size and very similar to RS2 
(Waldor and Mekalanos, 1996; Waldor et al., 1997). CTXΦ is present in the 
two available chromosomes in classical biotype strains of V. cholerae 
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serogroup O1 (Mekalanos, 1983; Trucksis et al., 1998), but only in the large 
chromosome of El Tor biotype strains of V. cholerae serogroup O1 
(Mekalanos et al., 1983; Pearson et al., 1993). Non-pathogenic strains of V. 
cholerae may be converted to pathogenic strains by phage transduction of 
CTXΦ. This could conceivably take place in the gastrointestinal environment 
and would result in the production of a new pathogenic strain of V. cholerae 
(Reidl and Klose, 2002). 
 
 
 
 
 
Figure 1.7 Schematic representation of CTXΦ 
Table 1.1 ORFs within the V. cholerae CTXΦ 
ORF           Length            Homologous protein* 
                     (aa) 
VC1452 78  RstC protein  
VC1453 124  RstB1 protein  
VC1454 359  RstA1 protein (phage replication initiation protein) 
VC1455 112  Transcriptional repressor RstR  
VC1456 124  Cholera enterotoxin, B subunit  
VC1457 258  Cholera enterotoxin, A subunit  
VC1458 399  Zona occludens toxin  
VC1459 97  Accessory cholera enterotoxin  
VC1460 427  Hypothetical protein  
VC1461 82  Colonization factor  
VC1462 127  RstB2 protein  
VC1463 359  RstA2 protein  
VC1464 112  Transcriptional repressor RstR 
 
*Homology based on BLASTP database analysis. 
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1.7.2 Vibrio pathogenicity island-1 (VPI-1) or TCP island  
The term “pathogenicity island” requires that certain criteria are met, for 
example, it should be located within an unstable region of a chromosome, be 
of different GC content in comparison to the residual genome, be allied with a 
tRNA gene, contain an IS (insertion sequence) element near the integrase 
and finally the element should be absent in a non-pathogenic strain (Hacker et 
al., 1997). One of the vital components thought to be involved in colonization 
of V. cholerae in the small intestine is TCP (toxin coregulated pilus). TCP 
Island or VPI-1 (Figure 1.8) is the part of a region of pathogenic strains of 
V. cholerae which is about 40 kb in size with low GC content (35%) flanked on 
both sides by 20-bp att-like sequences, and consists of TCP-ACF (accessory 
colonization factor) gene clusters, the integrase and a transposase gene 
(Karaolis et al., 1998; Kovach et al., 1996). The gene tcpA (vc0828) encodes 
the major subunit of TCP, but the total formation and the function of TCP 
require proteins encoded by the tcp gene cluster (Ogierman et al., 1993). For 
example, the gene product of tcpH and tcpI influence TcpA synthesis, where 
tcpI acts as a negative regulator and tcpH is a positive regulator of pilin 
synthesis (Harkey et al., 1994). As part of tcp gene cluster, a total of 15 ORFs 
(VC0825-VC0839, Table 1.2) are located downstream of tagD gene (vc0824). 
The acf gene cluster is present downstream of the tcp gene cluster. The true 
functions of these genes have not been discovered with the exception of 
accessory colonization factor, acfD (vc0845), which encodes a lipoprotein 
(Kovach et al., 1996). TCP can also act as a receptor of CTXΦ for infecting 
new strains (Waldor and Mekalanos, 1996).  
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Figure 1.8 Schematic representation of TCP island or VPI-1 (VC0817-
VC0847) 
Table 1.2 ORFs within the TCP island or VPI-1 (VC0817-VC0847) 
ORF      Length       Homologous protein* 
                (aa) 
VC0817 327  Transposase 
VC0817 226  No significant match 
VC0819 541  Aldehyde dehydrogenase  
VC0820 1013  ToxR-activated gene A protein  
VC0821 379  Hypothetical protein  
VC0822 1112  Inner membrane protein, putative  
VC0823 312  Hypothetical protein  
VC0824 164  TagD protein ; thiol peroxidase, atypical 2-Cys peroxiredoxin 
VC0825 620  Toxin co-regulated pilus biosynthesis protein I  
VC0826 221  Toxin co-regulated pilus biosynthesis protein P  
VC0827 136  Toxin co-regulated pilus biosynthesis protein H  
VC0828 224  Toxin co-regulated pilin  
VC0829 430  Toxin co-regulated pilus biosynthesis protein B  
VC0830 150  Toxin co-regulated pilus biosynthesis protein Q 
VC0831 489  Toxin co-regulated pilus biosynthesis outer membrane protein C 
VC0832 151  Toxin co-regulated pilus biosynthesis protein R  
VC0833 278  Toxin co-regulated pilus biosynthesis protein D  
VC0834 152  Toxin co-regulated pilus biosynthesis protein S  
VC0835 503  Toxin co-regulated pilus biosynthesis protein T  
VC0836 340  Toxin co-regulated pilus biosynthesis protein E  
VC0837 338  Toxin co-regulated pilus biosynthesis protein F  
VC0838 276  TCP pilus virulence regulatory protein 
VC0839 253  Toxin co-regulated pilus biosynthesis protein J  
VC0840 626  Accessory colonization factor AcfB 
VC0841 256  Accessory colonization factor AcfC 
VC0842 157  Hypothetical protein  
VC0843 302  TagE protein  
VC0844 215  Accessory colonization factor AcfA 
VC0845 1520  Accessory colonization factor AcfD 
VC0846 229  No significant match 
VC0847 422  Phage family integrase 
 
*Homology based on BLASTP database analysis. 
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1.7.3 Vibrio seventh pandemic island-1 (VSP-1)  
VSP-1 is a chromosomal island specific to the V. cholerae seventh pandemic 
strain of O1 El Tor and O139 serogroup isolates and is absent in more than 
100 non-O1 and non-O139 and TCP negative O1 strains (Dziejman et al., 
2002; Faruque and Mekalanos, 2003). VSP-1 is a 16 kb region, ranging from 
VC0175 to VC0185 (Table 1.3 and Figure 1.9), and has a low GC contents 
(40%) compared to the rest of the genome (47%). The low GC contents also 
reflect the recent acquisition of this island. Among 11 genes of VSP-1, seven 
of them were annotated as hypothetical proteins. The C-terminal domain of 
VC0175 shows similarity to deoxycytidylate deaminase-related proteins. The 
protein deaminase has various functions including nucleotide scavenging or 
DNA uptake during competence (Ribeiro et al., 1997; Richter et al., 1997). 
VC0176 might be a regulatory gene as it encodes a product which is 
paralogous to a family that includes RstR, a lysogeny repressor protein for 
CTXΦ (Dziejman et al., 2002). VC0178 is homologous to different 
phospholipases and VC0185 is a transposase which is similar to Tn554 in 
Staphylococcus  aureus (Murphy et al., 1985). 
 
 
 
 
 
Figure 1.9 Schematic representation of VSP-1 (VC0175-VC0185) 
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Table 1.3 ORFs within VSP-1 (VC0175-VC0185) 
ORF           Length            Homologous protein* 
                     (aa) 
VC0175 532  Deoxycytidylate deaminase-related protein  
VC0176 102  Transcriptional regulator, putative  
VC0177 187  Hypothetical protein  
VC0178 355  Patatin-related protein ; K06900 
VC0179 436  Hypothetical protein  
VC0180 584  Hypothetical protein  
VC0181 156  Hypothetical protein  
VC0182 143  Hypothetical protein  
VC0183 703  Hypothetical protein  
VC0184 562  Hypothetical protein  
VC0185 404  Transposase, putative  
 
*Homology based on BLASTP database analysis. 
 
1.7.4 Vibrio seventh pandemic island-2 (VSP-2)  
Like VSP-1, VSP-2 is a chromosomal island which is also specific to the 
V. cholerae seventh pandemic strain of O1 El Tor and O139 serogroup 
isolates and is absent in other non-pathogenic strains (Dziejman et al., 2002; 
Faruque and Mekalanos, 2003). In 2002, VSP-2 was initially identified as a 
7.5 kb region consisting of 8 ORFs which includes locus vc0490 to vc0497 
(Dziejman et al., 2002). In 2004, however, it was discovered that the island is 
much bigger than previously thought, about 27 kb and including the locus 
vc0490 to vc0516 (O'Shea et al., 2004a). VSP-2 consists of 24 functional 
ORFs and 3 non functional ORFs (Figure 1.10 and Table 1.4). The non-
functional ORFs are VC0499, VC0500 and VC0501 which contain an 
authentic frame shift that is not the result of a sequencing artifact (Heidelberg 
et al., 2000). The overall GC content of VSP-2 is 43% whereas the overall GC 
contents of the V. cholerae genome is 47%. This difference reflects the typical 
characteristics of pathogenicity islands. VSP-2 ORFs also encodes 
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homologues of an RNase H1 protein (VC0498), a type IV pilus (VC0502), a 
lysostaphin peptidase (VC0503), a DNA repair protein (VC0510), two 
transcriptional regulators (VC0497 and VC0513), two methyl-accepting 
chemotaxis proteins (VC0512 and VC0514), a P4-like integrase (VC0516) 
adjacent to the tRNA-methionine locus (vc0517.1) and 15 hypothetical 
proteins (VC0490-VC0496, VC0504-VC0509, VC0511 and VC0515) (O'Shea 
et al., 2004a). The pathogenicity island VSP-II shows homology to the 43.4 kb 
genomic island-I (VVI-I) of Vibrio vulnificus, a deadly human pathogen. 
V. cholerae ORFs VC0493–VC0498, VC0504–VC0510 and VC0516 are 
homologous to Vibrio vulnificus strain YJ016 ORFs VV0510–VV0516, 
VV0518–VV0525 and VV0560, respectively. The amino acid sequence 
identities of some ORFs in homologous regions of both islands are greater 
than 90% (O'Shea et al., 2004a). 
VSP-1 and VSP-2 were acquired by horizontal gene transfer, but the exact 
mechanism by which the current pandemic strains containing those 
chromosomal island evolved is still to be discovered. These islands may have 
been integrated into pre-seventh pandemic strain of V. cholerae El Tor O1 
which already held TCP and CTXΦ. Another possibility could be the 
acquisition of VSP islands followed by gaining TCP and CTXΦ in non-
pathogenic El Tor O1 strain (Figure 1.4). However, the success of the current 
pandemic strain over the last 48 years reflects its survival fitness in the host 
and the environment, as even after all these years it is still devastating and 
spreading faster than before. These islands could also be responsible for 
efficient infection in humans by allowing resistance to stomach acids, 
prolonged intestinal colonization etc (Dziejman et al., 2002).  
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Figure 1.10 Schematic representation of VSP-2 (O'Shea et al., 2004a). 
Table 1.4 ORFs within VSP-2 (VC0490-VC0516) 
ORF           Length            Homologous protein* 
                     (aa) 
VC0490             653  Hypothetical protein  
VC0491 178  Hypothetical protein  
VC0492 388  Hypothetical protein  
VC0493 291  Hypothetical protein  
VC0494 214  Hypothetical protein  
VC0495 224  Hypothetical protein  
VC0496 199  Hypothetical protein  
VC0497 66  Transcriptional regulator 
VC0498 146  Ribonuclease H  
VC0499 276  No significant match 
VC0500 112  No significant match 
VC0501 302  No significant match 
VC0502 174  Type IV pilin, putative  
VC0503 426  Lysostaphin peptidase 
VC0504 75  Hypothetical protein  
VC0505 122  Hypothetical protein  
VC0506 244  Hypothetical protein  
VC0507 58  Hypothetical protein  
VC0508 147  Hypothetical protein  
VC0509 147  Hypothetical protein  
VC0510 157  DNA repair protein RadC-related protein 
VC0511 39  Hypothetical protein  
VC0512 529  Methyl-accepting chemotaxis protein 
VC0513 271  Arac/Xyls family transcriptional regulator  
VC0514 626  Methyl-accepting chemotaxis protein 
VC0515 410  Hypothetical protein  
VC0516 413  Phage integrase 
 
*Homology based on BLASTP database analysis. 
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1.7.5 Vibrio pathogenicity island-2 (VPI-2) 
VPI-2 is a 57.3 kb region which consists of 52 ORFs (VC1758 to VC1809) 
present in all pathogenic O1 and O139 serogroup isolates, but lacking in non-
O1 and non-O139 non-pathogenic isolates (Figure 1.12), (Jermyn and Boyd, 
2002). VPI-2 is 57 kb in length and the GC contents is 42% compared to 47% 
for the entire V. cholerae genome. Among 52 ORFs (Figure 1.11 and Table 
1.5), 29 ORFs are homologous to genes of known function including 
hypothetical proteins, 13 ORFs are homologous to bacteriophage genes, and 
10 ORFs do not show any significant match in the database. VPI-2 encodes 
an integrase (VC1758), which is similar to the integrase found in VPI-1 
(Karaolis et al., 1998). In VPI-2, a different gene cluster was also observed, 
such as type 1 restriction modification system (VC1764-VC1769), which 
shows similarity to another restriction modification system found in 
Xylella fastidiosa (Simpson et al., 2000). Another region, named nan-nag 
region (VC1773-VC1784) next to the type 1, shows sequence similarity to 
another gene cluster present in the Haemophilus influenzae genome which 
encodes enzymes that are involved in utilization of amino sugars 
(Fleischmann et al., 1995; Jermyn and Boyd, 2002).  
The nanH gene encodes neuraminidase (VC1784) which can act on higher 
gangliosides and convert them to GM1 gangliosides that results in the release 
of sialic acid. This sialic acid could be utilized by the proteins encoded by the 
nan-nag region and may provide alternative nutrient sources for pathogenic 
V. cholerae strains (Galen et al., 1992; Jermyn and Boyd, 2002; Vimr et al., 
2004). VPI-2 has another phage like region (VC1791-VC1799) upstream of 
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two consecutive IS (insertion sequence) like elements (VC1789-VC1790). 
VPI-2 has an unstable region between VC1760 (helicase) and VC1789 
(IS911-like element), which includes the restriction modification system and 
the nan-nag regions. This region is deleted from 13 of the 14 V. cholerae 
O139 serogroup strains examined (Figure 1.12) (Jermyn and Boyd, 2002). 
 
 
 
 
 
Figure 1.11 Schematic representation of the 57.3 kb VPI-2 (Jermyn and 
Boyd, 2002) 
 
 
 
 
 
 
Figure 1.12 Structural organization of VPI-2 in V. cholerae. * A full VPI-2 
could also be present in V. cholerae O139 strain. ** includes both V. cholerae 
O1 and non-O1/non-O139 strain (Jermyn and Boyd, 2002). 
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Table 1.5 ORFs within VPI-2 (Jermyn and Boyd, 2002) 
ORF         Length     Homologous protein (organism)* 
                   (aa) 
 
VC1758   411  Integrase (V. cholerae)  
VC1759   159  Integrase (V. cholerae)  
VC1760   940  Helicase (Bacillus subtilis)  
VC1761   202  No significant match  
VC1762   483  No significant match 
VC1763   244  Chemotaxis protein MotB (Aquifex aeolicus)  
VC1764   706  Methyl-accepting subunit (Deinococcus radiodurans)  
VC1765   1022  Restriction enzyme helicase subunit (Xylella fastidiosa)  
VC1766   663  Hypothetical protein (P. multocida)  
VC1767   470  Hypothetical protein NMA2230 (Neisseria meningitidis)  
VC1768   462  Type I restriction enzyme (Xylella fastidiosa) 
VC1769   793  Type I restriction DNA methylase (Xylella fastidiosa)  
VC1770  687  No significant match  
VC1771   1220  No significant match  
VC1772   286  Hypothetical protein NMA1157 (Neisseria meningitidis)  
VC1773   356  Hypothetical protein HI0148 (Haemophilus influenzae)  
VC1774   384  Hypothetical protein HI0148 (H. influenzae)  
VC1775   278  Hypothetical protein HI0143 (H. influenzae)  
VC1776   298  N-Acetylneuraminidase lyase HI0142 (H. influenzae)  
VC1777   427  C4-Dicarboxylase transporter HI0147 (H. influenzae)  
VC1778   173  C4-Dicarboxylase transporter HI0147 (H. influenzae)  
VC1779   321 C4-Dicarboxylase binding protein HI0146 (H. influenzae) 
VC1780   97   No significant match  
VC1781   240  N-Acetylmannosamine-6-phosphate 2-epimerase (H. influenzae) 
VC1782   287  N-Acetylmannosamine amide kinase (H. influenzae) 
VC1783   378  N-Acetylamide glucosamide-6-phosphate deacetylase (H. influenzae) 
VC1784   807  Neuraminidase (Bacteroides fragilis) 
VC1785   68   DNA binding protein (P4 bacteriophage)  
VC1786   158 RadC DNA repair (Xylella fastidiosa) 
VC1787   45   No significant match 
VC1788   231  Hypothetical protein chromosome II (V. cholerae)  
VC1789   290  IS911  
VC1790   114 IS911  
VC1791   346  Mu-like gp42 (Mu prophage)  
VC1792   119  Mu-like gp41 (Mu prophage) 
VC1793   125  Transposase (Caenorhabditis elegans)  
VC1794   192  gp12 protein (PSA bacteriophage)  
VC1795   106  MOR protein (Mu phage)  
VC1796   124  MOR protein (Mu phage)  
VC1797   153  No significant match  
VC1798   383  Eha protein (Salmonella typhi) 
VC1799   585  Integrase (Salmonella typhimurium LT2)  
VC1800   323  Plasmid replication protein C (Clostridium butyricum)  
VC1801   120  No significant match  
VC1802   78   Transcriptional regulator (Salmonella typhi)  
VC1803   153  Repressor protein (CP-933O prophage) 
VC1804   104  Hypothetical protein VC0509 (V. cholerae)  
VC1805   148  Hypothetical protein VC0508 (V. cholerae) 
VC1806   328  Replicase (Fr bacteriophage)  
VC1807   214  No significant match  
VC1808   281  No significant match  
VC1809   76   Vis protein (P4 bacteriophage)  
 
*Homology based on BLASTP database analysis. 
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1.7.6 Other pathogenicity factors 
1.7.6.1 Integron islands 
Integrons are genetic elements which have sophisticated gene capture 
systems which can, by site-specific recombination, recognize and capture 
mobile gene cassettes. Typically an integron contains an integrase gene 
cassette, captured gene cassettes and an integration site for the gene 
cassettes (Fluit and Schmitz, 2004; Hall and Collis, 1995). In V. cholerae, the 
integron island is a 125.3 kb gene cluster which is part of the gene capture 
and expression system. It is possible that integron lslands in V. cholerae 
express capture genes to enhance pathogenicity, in response to stress and 
the resistance against antimicrobial compounds (Faruque and Mekalanos, 
2003). 
1.7.6.2 RTX gene cluster 
The RTX gene cluster (VC1447-VC1451) is a 10 kb region which encodes 
cytotoxin RtxA, an acyltransferase RtxC and an associated ABC transporter 
system RtxB/D. This gene cluster is physically related to the CTXΦ and is 
responsible for the cytotoxic activity in V. cholerae O1 El Tor and O139 strain. 
the RTX gene cluster may contribute to the residual adverse effects of certain 
live attenuated cholera vaccines (Lin et al., 1999; O'Shea et al., 2004b). 
1.7.6.3 Type IV-A pilus gene cluster 
The V. cholerae Type IV-A pilus gene cluster is 5.4 kb in size, and consists of 
five ORFs named PilA, PilB, PilC, PilD and YacE. This gene cluster also 
shows similarity to other type IV-A pilus gene clusters present in different 
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organisms. The pilD gene product is essential for the secretion of CT and is 
also important for the production of toxin-coregulated pili which is an important 
colonization factor in the host (Fullner and Mekalanos, 1999). 
1.8 Role of iron in pathogenicity 
In nearly all living organisms, iron is an essential element for survival as it is 
required for cellular metabolism, DNA metabolism, response to oxidative 
stress, the tricarboxylic acid (TCA) cycle, toxicity and pathogenesis. 
Regulation, transport and maintenance of iron in cells are vital (Andrews et 
al., 2003; Wandersman and Delepelaire, 2004). At biological pH, ferric iron is 
poorly soluble (10-18 M), and is not easily available. In mammalian hosts, free 
iron is maintained by the action of iron binding proteins such as the 
extracellular transferrin and lactoferrin; and the intracellular ferritin, 
hemosiderin and heme. Transferrin, a human iron acquisition protein, contains 
30% saturated iron and exhibits high association with ferric iron (Fe3+). 
Therefore, the free iron concentration in plasma is very low, at around 10-18 M 
(Sritharan, 2006). Although iron is important for microbes, a high 
concentration of iron in the cell is lethal for them as it leads to the production 
of reactive hydroxyl radicals via the Haber-Weiss and Fenton reactions 
(Haber and Weiss, 1932) . 
A successful pathogen can obtain iron from the host cell by synthesized 
siderophores which are low molecular weight Fe3+-specific ligand which are 
able to chelate iron from host iron-binding proteins. Alternatively, pathogens 
can uptake iron directly by producing receptors specific to host iron-containing 
molecules such as heme, hemoglobin, transferrin and lactoferrin (Braun et al., 
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1998). V. cholerae has multiple systems for iron acquisition from the human 
host and environmental niches including siderophore synthesis and transport, 
receptors for heme and hemoglobin, TonB system, ABC transporters etc 
(Wyckoff et al., 2007). It is clear that the host contains very low levels of free 
iron and the pathogen requires a higher concentration of iron in order to 
multiply in host environments. In iron limiting situations in the host, the 
bacteria triggers a signal that activates virulence genes to kill host cells for 
nutrition including iron. Interestingly, huge numbers of virulence genes are 
regulated by ferric uptake regulator (Fur). In Pseudomonas aeruginosa, for 
example, expression of alternative sigma factor is regulated by Fur, which 
leads to the transcription of some virulence genes such as endoprotease 
(PrpL) and exotoxin A (Leoni et al., 1996; Ochsner et al., 1996; Wilderman et 
al., 2001). 
1.9 Ferric uptake regulator of V. cholerae 
The ferric uptake regulator of V. cholerae (VcFur) is a dimeric metalloprotein 
of monomeric size ~17 kDa with an N-terminal domain involved in DNA 
recognition domain and a C-terminal domain involved in dimerization (Coy 
and Neilands, 1991; Stojiljkovic and Hantke, 1995). Regulation of iron 
acquisition genes in V. cholerae is mediated primarily through the VcFur 
protein. The N-terminal domain contains a winged helix motif which helps to 
bind a 19-bp inverted repeat sequence known as a Fur-box (Escolar et al., 
1999). As a classical repressor, the main function of Fur is iron homeostasis. 
It also helps organisms to survive acidic environments or stress (Hall and 
Foster, 1996). When iron levels are high, Fur binds to the Fur-box and 
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prevents access of RNA polymerase to the downstream iron acquisition 
genes whereas in the presence of low iron, derepression of the iron uptake 
genes occurs (Figure 1.13) (Andrews et al., 2003). A variety of VcFur 
homologues have been discovered in a wide range of Gram-negative human 
pathogens such as Salmonella typhimurium (Ernst et al., 1978), 
Yersinia pestis (Staggs and Perry, 1991), Helicobacter pylori (Bereswill et al., 
1998), Pseudomonas aeruginosa (Prince et al., 1993), Bordetella pertussis 
(Brickman and Armstrong, 1995), Neisseria gonorrhoeae (Berish et al., 1993) 
and Haemophilus ducreyi (Carson et al., 1996). In Gram-positive bacteria 
such as Bacillus subtilis (Bsat et al., 1998) and Staphylococcus epidermidis 
(Heidrich et al., 1996), Fur-like proteins have been characterized. 
Iron and Fur regulation in V. cholerae has been extensively studied and it has 
been shown that VcFur has both negative and positive regulatory functions 
and is able to repress almost all of the iron acquisition genes during iron-
replete conditions (Mey et al., 2005). In addition, genes encoding the toxin-
coregulated pilus (TCP) and the large integron are positively regulated by 
VcFur. As an activator, Neisseria meningitidis Fur protein can bind upstream 
of the target gene promoters that subsequently initiate positive regulation 
in vivo (Delany et al., 2004). 
A strain of V. cholerae with the fur gene knocked out shows very weak 
autoagglutination that is possibly due to defective expression or assembly of 
the TCP, an important virulence factor. In infant mouse studies, it was found 
that the fur knockout strain colonized poorly compared to a wild type strain of 
V. cholerae. In practice, VcFur can control the expression of more than 100 
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genes in V. cholerae in an iron-dependent or iron-independent manner (Mey 
et al., 2005). 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
Figure 1.13 Schematic representation of Fur-mediated gene repression 
(Andrews et al., 2003). 
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1.10 Antibiotic resistance of V. cholerae 
Antibiotic resistant pathogenic strains of V. cholerae are becoming a major 
challenge. Uptake of foreign genetic material by horizontal gene transfer is the 
primary cause of evolution of multi-drug resistant (MDR) strains of V. cholerae 
(Sack et al., 2001). Widespread antibiotic resistance to V. cholerae was 
reported after 1977 in Tanzania and Bangladesh (Glass et al., 1980; Mhalu et 
al., 1979). In the past two decades, reports generated from countries where 
cholera is endemic have shown V. cholera to be resistant to several 
commonly used antibiotics including tetracycline, ampicillin, kanamycin, 
streptomycin, sulphonamides, trimethoprim and gentamicin. Unlike 
Shigella spp, which show rising resistance to antibiotics, V. cholerae O1 and 
O139 show spatial and temporal fluctuations, with periods of fluctuating 
resistance or sensitivity indicating the possible misuse of antibiotics during 
treatment programs (Sack et al., 2001). 
1.11 Prevention and treatment of cholera 
The primary steps that could be useful in reducing the transmission of cholera 
includes the provision of a safe water supply, improvement of sanitation and 
hygiene, ensuring that food is fully cooked and health education. 
Unfortunately, in the developing world, where cholera is a particular problem, 
improvements in infrastructure for water and sanitation facilities has a long 
way to go (Sack et al., 2004). Replacing lost fluid and ions in order to prevent 
further dehydration is used as the major form of palliative care for patients 
infected with V. cholerae. In most cases, oral rehydration solution (ORS) is 
given to the patient. The therapy of the patient is guided by the degree of 
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dehydration. For severe cases, emergency intravenous polyelectrolyte 
solution for rehydration followed by ORS is required for maintaining hydration 
inside the body of the patient. In cases of milder dehydration, ORS is used for 
both rehydration and maintenance. The principles of rehydration therapy 
include a rapid replacement of fluid deficits; correction of the metabolic 
acidosis; correction of potassium deficiency; and replacement of continuing 
fluid losses.  The case-fatality rate for severe cholera is about 50% without 
treatment (Sack et al., 2004). A course of antibiotics is usually given to 
patients with severe cholera, but the effectiveness of antimicrobial drugs is 
limited by antimicrobial resistance resulting in potential increased risk of 
V. cholerae (Sack et al., 2001). 
In addition, soon after the discovery of V. cholerae as a cause of cholera, an 
anti-cholera vaccine was developed. From this point, the whole cell, injectable 
vaccine was used as a preventative method for disease control. However, the 
vaccine was shown to have only a very limited effectiveness and was 
withdrawn from use (Sack et al., 2004). Currently, different research groups 
are trying to develop a new vaccine for cholera which includes a few selected 
antigens derived from the pathogen, but no potential breakthrough has been 
made so far. It would be of great socioeconomic benefit to develop a safe 
vaccination agent against V. cholerae in order to protect from cholera and to 
alleviate the threat of the forthcoming eighth pandemic. 
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1.12 Overall project aims and background 
The progress in the development of novel agents to fight against cholera has 
been slowed down during the past decade partly because of the success of 
ORS in reducing mortality and partly because of limited commercial interest in 
drugs for the developing world. The main objective of my study is to assist in 
the discovery of an effective drug against cholera and find a novel vaccination 
target using bioinformatics, molecular biology and structural proteomics to 
investigate the specific protein targets derived from pathogenic V. cholerae. It 
is hoped that the structural insight of these pathogenicity factors will improve 
our understanding of how these contribute to disease. 
The first part of my PhD project was working on proteins of interest in VPI-2 
which encodes several gene clusters and is likely to be important in 
pathogenesis. My particular interest is in determining the structures and 
ascribing functions to conserved hypothetical proteins and their homologues 
and paralogues in the reduced 20 kb VPI-2 region (VC1789 to VC1809), 
present in all pathogenic strain of V. cholerae O1 El Tor and O139 and 
missing in non-pathogenic strain (Jermyn and Boyd, 2002). One such 
conserved hypothetical protein is VC1805 and its four copies of 
homologous/ paralogous ORFs present in VPI-2 (VC1804 and VC1805) and 
VSP-2 (VC0508 and VC0509). In addition to the structure determination of 
these proteins, I want to answer some more questions: What is their function? 
How do they impart pathogenicity? Do they interact with host proteins? Are 
they potential therapeutic targets? 
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The second part of my PhD project was working on VcFur which is a well 
known metal-dependent DNA-binding protein that acts as both a repressor 
and activator of numerous genes involved in maintaining iron homeostasis in 
bacteria and virulence expression. Fur can be considered as one of the most 
promising novel drug targets against bacteria because in eukaryotic 
organisms, no homologues of Fur have been found so far. The fur deletion 
mutant shows reduced virulence in some pathogenic organisms like 
V. cholerae (Mey et al., 2005) and Pseudomonas aeruginosa (Vasil and 
Ochsner, 1999). The Fur protein from Mycobacterium tuberculosis has also 
been identified as a potential novel drug target (Lucarelli et al., 2008). Despite 
being a highly promising drug target, progress has not been advanced since 
the first discovery of the Fur family more than twenty years ago. This is 
because of the lack of studies of the functional diversity of this protein family 
in a variety of organisms and the lack of any structural details about Fur-DNA 
complex regulation. This project was aimed to solve the structures of VcFur 
and VcFur-DNA complex and to investigate its functional characterization 
including metal interaction which could provide important clues for future drug 
design. 
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2. Materials and methods 
This chapter describes the general methods used in this project. 
2.1 Strains and preparation of genomic DNA 
The Vibrio cholerae strain used for this study is V. cholerae O1 El Tor strain 
N16961 and was kindly provided by Dr. E. Fidelma Boyd (University of 
Delaware). All strains were grown in Luria–Bertani (LB) broth and stored as 
frozen stocks in LB broth with 20% (v/v) glycerol. Genomic DNA (gDNA) was 
prepared from this strain by using the Easy-DNA kit (Invitrogen) according to 
the manufacturers’ instructions. The following E. coli strains were used as 
cloning and expression hosts: 
Strain Organism 
BL21 (DE3) Escherichia coli 
Rosetta (DE3) E. coli 
DH5α E. coli 
DH5α λpir E. coli 
K12 strain TB1 E. coli  
 
2.2 Target proteins 
A total of five proteins were targeted for crystallization, of which four are from 
pathogenicity islands and the fifth is the ferric uptake regulator (Table 2.1). 
Table 2.1 Target proteins in Vibrio cholerae 
ORF Length (aa) Function 
VC1805 148 Hypothetical protein in VPI-2 
VC1804 104 Hypothetical protein in VPI-2 
VC0508 147 Hypothetical protein in VSP-2 
VC0509 147 Hypothetical protein in VSP-2 
VC2106 150 Transcriptional regulator, iron homeostasis 
 36 
2.3 Vectors 
2.3.1 pEHISTEV vector 
The pEHISTEV vector, is an engineered variant of pET30 with an N-terminal 
6X His-tag that is cleavable using tobacco etch virus (TEV) protease and 
leaves two additional residues (Gly-Ala) at the N-terminus (Liu and Naismith, 
2009). 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 pEHISTEV vector 
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2.3.2 pLou3 vector 
pLou3 is an engineered variant of NEB vector pMAL-c2X with an N-terminal 
6X His-tag maltose binding protein (HMBP) that is cleavable using Tobacco 
Etch Virus (TEV) protease, and a lacZα complementation gene present after 
the MCS (multiple cloning sites) (Dr Louise Major, personal communication). 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2 pLou3 vector 
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2.3.4 pCR2.1-TOPO vector 
The pCR2.1-TOPO vector was purchased from Invitrogen, USA 
(www.invitogen.com). The vector is supplied linearized with single 3´-
thymidine (T) overhangs for TA Cloning. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3 pCR2.1-TOPO cloning vector 
 39 
2.3.5 pDS132 vector 
pDS132 is an engineered variant of suicide vector pCVD442 (Donnenberg 
and Kaper, 1991) which contains R6K ori, the replication origin of plasmid 
R6K, the mob RP4, a plasmid mobilisation regions, cat, chloramphenicol 
resistance and sacB gene, a suicide marker . 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4 Suicide vector pADS132 
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2.4 Polymerase chain reaction (PCR)  
The target genes were amplified by polymerase chain reaction (PCR) from 
genomic DNA of V. cholerae O1 El Tor strain N16961. Forward and reverse 
primers were designed corresponding to the 5′ and complementary 3′ ends of 
target genes with specific recognition sites such as NcoI, EcoRI, SalI etc. 
PCRs were performed in a volume of 50 µL containing 1 µL of forward primer 
(50 µM), 1 µL of reverse primer (50 µM), 5 µL PCR buffer (10X), 100 ng DNA 
which was heated at 70 °C for 3 min, 1 µL of 10 mM deoxynucleotide 
triphosphates (dNTPs), 1 µL pfu DNA polymerase and water up to 50 µL. The 
amplification conditions were: pre-incubation at 94 °C for 5 min, followed by 
30 cycles of 94 °C for 1 min, X °C for 1 min (X °C = 5 °C below primers’ Tm) 
and 72 °C for Y min (Y min = 1 min per kb of nucleotide). Before storing at 
4 °C samples were heated at 72 °C for 10 min for extension. 
2.5 Agarose gel electrophoresis 
Agarose gel electrophoresis was carried out to visualize all the amplified PCR 
products for subsequent purification. For a 0.8% gel (which is normally used), 
0.8 g of agarose was dissolved in 100 mL 1X Tris-Acetate-EDTA (TAE) buffer. 
Solutions were cooled slightly before addition of 5 µL of 10 mg/mL ethidium 
bromide and then poured into a mould. DNA samples were prepared by 
adding 6X gel loading solution and loaded into wells. DNA ladder (Promega), 
1 kb is used depending on the product size. Gels were run at 120 V for 
45 min.  
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2.6 Restriction digestion of PCR products and vector 
The product band of target genes were excised from the gel and purified by 
QIAquick Gel Extraction Kit (QIAGEN) that results in 50 µL of eluted DNA. To 
open the specific recognition sites in the PCR products and vector (such as 
pEHISTEV), 200 ng to 1 µg of PCR products/vector were digested with 3 µL 
of 10X BSA (freshly prepared, can be stored in -20°C), 3 µL restriction 
digestion buffer (10 X), 1 to 2.5 µL of each corresponding restriction enzyme 
(Promega) and water up to 30 µL. The samples were mixed gently by using 
micropipette, spun down for 3 to 5 s, and incubated at 37 °C for 2-3 h followed 
by 65 to 80 °C for 10 min to inactivate enzymes. Alternatively, for rapid 
restriction digestion, a 20 µL reaction mixture was prepared in a PCR tube 
with 200 ng to 1 µg of PCR products/vector, 10X FastDigest buffer 
(Fermentas), 1 µL of each corresponding enzyme (Fermentas) and nuclease-
free water up to 20 µL. The samples were mixed gently by using a 
micropipette, spun down for 3 to 5 s, and incubated for 5-15 min followed by 
65 to 80 °C for 10 min to inactivate enzymes. To check digestion efficiency, 
5 µL of restriction digestion product was run on an agarose gel 
electrophoresis.  
2.7 Ligation 
Different ratios of digested vector and insert have been used to optimize the 
ligation reaction. The use of 100 ng of DNA and a molar ratio of insert to 
vector of 3:1 is standard. The following formula is used to calculate the exact 
insert quantity to be needed for the ligation reaction. 
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ng of vector X kb size of insert             insert 
-----------------------------------------   X   -------------- (molar ratio)     =    ng of insert 
             kb size of vector                      Vector 
 
Ligation of digested vector and insert was carried out in a microcentrifuge 
tube using 2 µL 10 X ligation Buffer (Promega), 1 µL T4 DNA ligase 
(Promega), digested vector (1 to 16 µL, depending on concentration) and 
corresponding insert (1 to 16 µL, depending on concentration) and water up to 
20 µL. The samples were mixed gently using a micropipette, spun down for 
3 to 5 s then incubated at 22 °C for 1 h or 16 °C overnight.  
For rapid ligation, a 20 µL reaction mixture was prepared containing 4 µL 5X 
ligation Buffer (Fermentas), 1 µL T4 DNA Ligase (Fermentas), digested vector 
(1 to 14 µL, depending on concentration), corresponding insert (1 to 14 µL, 
depending on concentration) and nuclease-free water up to 20 µL. The 
samples were mixed gently using a micropipette, spun down for 3 to 5 s, and 
incubated for 5-15 min at 22 °C.  
2.8 Transformation  
5 µL of ligated DNA sample (5 to 50 ng) was transformed into 45 µL of 
competent cells such as E. coli DH5α, by cold shock (in ice 30-40 min), heat 
shock (in water bath 42 °C for 1 min) and cold shock (in ice 3-5 min). 950 µL 
of pre-warmed Luria-Bertani (LB) Media was added to the transformation 
reaction tube which was then placed horizontally in a shaking incubator 
(200 rpm) at 37 °C for 60-90 min. After incubation, the cells were spun down 
at 4000 rpm for 4 min and following removal of excess LB media, cells were 
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resuspended with the remaining LB supernatant. These transformed cells 
were plated on LB agar containing the appropriate antibiotic and incubated at 
37 °C overnight. Alternatively, If the vector contained any antibiotic resistance 
gene other than kanamycin, a rapid transformation protocol was used in which 
5 µL of ligated DNA sample (5 to 50 ng) was mixed with 45 µL of competent 
cells such as E. coli DH5α and incubated 5 min on ice and plated directly onto 
LB agar containing the appropriate antibiotic. 
2.9 Blue/white colony screening 
The substrate X-gal (5-bromo-4-chloro-3-indolyl-β-D-galactoside) is used to 
screen blue/white colonies on the plate. X-gal can be used by the bacterium if 
it is able to produce β-galactosidase. Cloning hosts such the E. coli DH5α 
strain do not contain the lacZα gene which is one of the active parts of β-
galactosidase, and can be complemented by vectors such as pLou3. In the 
presence of β-galactosidase, X-gal is cleaved into bromo-4-chloro-3-
hydroxyindole followed by oxidization to 5,5'-dibromo-4,4'-dichloro-indigo, an 
insoluble blue product which gives characteristic blue coloured colonies on 
the culture plate. Some constructs of pLou3 cannot complement lacZα gene if 
there is any disruption in the MCS due to the presence of our gene of interest. 
Transformed cells were spread on an LB plate containing 40 µL of 40 mg/mL 
X-gal, 40 µL of 100 mM IPTG and the appropriate antibiotic followed by 
incubation at 37 °C overnight. As X-gal is light sensitive, the stock was always 
wrapped with aluminium foil.  
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2.10 Confirmation of cloning  
2.10.1 Colony PCR 
Colonies containing recombinant vector DNA were identified using colony 
PCR screening. Several colonies were randomly picked by sterile toothpick 
and each resuspended in 10-15 µL water, then the wet toothpick was 
streaked on LB agar containing appropriate antibiotic and allowed to grow at 
37 °C overnight. The remainder of each suspension was heated at 99 °C for 
5 min before cell debris was removed by centrifugation. The cell free lysate 
was used in a PCR reaction containing 10 µL lysate, and 10 µL master mix 
which contained 0.2 µL 10 mM dNTPs, 0.2 µL 10X Taq DNA polymerase 
buffer, 0.2 µL DNA polymerase, 0.2 µL of 5 µM vector specific forward primer 
and 0.2 µL of 5 µM vector specific reverse primer and 9 µL of water. For the 
pEHISTEV vector, the primers used in colony PCR are T7 forward primer (5′-
TAATACGACTCACTATAGGG- 3′) and T7 terminator (5′ -
TATGCTAGTTATTGCTCAG- 3′). PCR reactions were carried out as 
described earlier (section 2.4). Colony PCR was analyzed by agarose gel 
electrophoresis. 
2.10.2 Double digestion 
As a further confirmation, double digestion of the cloned vector containing the 
gene of interest was carried out, using corresponding restriction enzymes 
according to the protocol described earlier (section 2.6). Then the sample was 
run on agarose gel to confirm the presence of the gene of interest. 
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2.10.3 DNA sequencing 
The correct sequence of cloned constructs was confirmed by sequencing 
using vector specific primers. For example, T7 forward and reverse primers 
were used to sequence the pEHISTEV vector. 500 ng of DNA in 30 µL water 
was sent to the sequencing service at the School of Life Sciences, University 
of Dundee, Scotland (www.dnaseq.co.uk). 
2.11 Purification of transformed vector DNA 
A transformed colony containing the recombinant vector was inoculated in 
10 mL LB containing the appropriate antibiotic followed by shaking incubation 
at 37 °C overnight. After incubation, cells were spun down at 3000 rpm for 
10 min at 4 °C. The pellet was collected and vector DNA was purified by the 
QIAquick spin protocol (QIAGEN), which elutes vector DNA in 30 to 50 µL of 
water. 
2.12 Transformation in expression host 
3 µL of purified recombinant vector was transformed into 50 µL of BL21 (DE3) 
and/or Rosetta (DE3) and/or C43 strain of E. coli using the protocol described 
earlier (section 2.8) followed by plating out on LB agar containing the 
appropriate antibiotic and incubated at 37 °C overnight.  
2.13 Protein expression trials and optimization of solubility 
A transformed expression host colony was used to inoculate 10 mL LB 
containing the appropriate antibiotic followed by shaking incubation at 37 °C 
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overnight. After incubation, 200 µL culture was inoculated in 10 mL LB and 
10 mL TPB (tryptose phosphate broth) containing the appropriate antibiotic, 
followed by shaking incubation at 37 °C for 2-3 h until an OD600 of 0.5-0.6 was 
reached. At this point, cells were exposed to various IPTG (isopropyl-beta-D-
thiogalactopyranoside) concentrations and temperatures (Table 2.2) to induce 
the expression of cloned genes. 1 mL of culture of each sample was 
centrifuged and the pellet were lysed using 200 µL cell lysis buffer BugBuster 
(Novagen). The whole cell and soluble sample were analysed by SDS-PAGE 
(sodium dodecyl sulfate-polyacrylamide gel electrophoresis) to confirm 
soluble protein expression. 
Table 2.2 Conditions used for the induction of expression of Targets 
 
2.14 SDS-PAGE  
Pre-cast 4- 12% Nupage gels were set up according to manufacturers’ 
instruction (Invitrogen). Rigs were filled with 800 mL 1 X MES buffer and 1 mL 
of antioxidant was added to the upper chamber. Loading buffer, 4X LDS was 
added to the protein samples followed by denaturation at 99 °C for 5 min and 
samples were loaded into wells alongside an appropriate unstained marker 
such as Mark12™ standard (Invitrogen). Electrophoresis was carried out at 
Expression 
(Shock) 
Expression 
Host 
(E. coli) 
Incubation 
temperature 
Incubation 
time 
IPTG 
concentration 
Heat shock 
or 
Cold shock 
or 
No shock 
Rosetta (DE3) 
or 
BL21 (DE3) 
or 
C43 (DE3) 
37 °C 
or 
25 °C 
or 
16 °C 
3 h 
or 
24 h 
or 
36 h 
1.0 mM 
or 
0.5 mM 
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200 volts (V) and a current of 70-115 mA for 35 min. On completion, gels 
were stained with Coomassie Blue to allow protein detection.  
2.15 Mass spectrometry 
Mass spectrometry is an important method for protein molecule identification. 
The protein, either in solution or as a band excised from an SDS-PAGE gel, 
was submitted to the mass spectrometry and proteomics facility in the 
University of St Andrews. Tryptic fragments of the protein were analyzed by 
MALDI-TOF MS (matrix-assisted laser desorption/ionization-time of flight 
mass spectrometry) and MS/MS (tandem mass spectrometry) using a 4800 
MALDI-TOF/TOF analyzer (Applied Biosystems).  
2.16 Bulk-scale purification of target protein 
2.16.1 Nickel column purification 
The recombinant protein expressed from the pEHISTEV/ pLou3 vector, 
contained an N-terminal 6X His-tag. The cell pellet was resuspended in an 
appropriate solubilizing buffer (such as 50 mM HEPES, 500 mM NaCl, 10 mM 
imidazole and 10% (v/v) glycerol), which is usually made up with high salt 
concentration, containing 5 µg/mL DNase I and EDTA-free protease inhibitor 
cocktail (Roche Applied Science) and sonicated. After centrifugation, the 
soluble fragment was syringe filtered through a 0.22 µm filter unit (Millipore) 
and the target protein was purified using a HisTrap™ HP column (Ni2+-affinity 
column, GE Healthcare), according to the manufacturers’ instructions. 
Purification of target proteins was also confirmed by SDS-PAGE.  
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2.16.2 6X His-tag cleavage 
His-tag cleavage was done in dialysis buffer (appropriate solublizing buffer) in 
the presence of DTT (Dithiothreitol) and/or EDTA (ethylenediaminetetraacetic 
acid). TEV (Tobacco Etch Virus) protease was added into the dialysis tube 
containing His-tagged protein (1 µg protease for 1 mg at 25 °C overnight). The 
digested protein sample was analysed by SDS-PAGE to check the efficiency 
of TEV protease digestion. 
To remove EDTA and/or DTT, the digested sample was dialysed against the 
same dialysis (for TEV cleavage) buffer without EDTA and/or DTT. Protein 
samples were syringe filtered and loaded into the nickel column as before and 
the flow-through was collected in fractions and analysed by SDS-PAGE. As 
the 6X His-tag is cleaved from the protein, it should bind to the nickel column 
and the proteins will be eluted in the flow-through. The corresponding 
fractions were pooled, dialysed and concentrated using an appropriate 
centrifugal concentrator (Sigma- Aldrich) to prepare the samples for gel 
filtration column chromatography for further purification. 
2.16.3 Gel filtration chromatography 
In the final stage of purification, up to 4.5 mL of sample was loaded onto a 
Hiprep 16/60 Sephacryl S-200 gel filtration column (GE Healthcare) 
according to the manufacturers’ protocol. Samples from the observed peaks 
were analysed separately by SDS-PAGE. 
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2.17 Pre crystallization test 
The PCT™ (Pre-Crystallization Test) is used to determine the appropriate 
protein concentration for crystallization screening. Sample concentration is a 
significant crystallization variable. If the samples are too concentrated they 
can result in amorphous precipitate, while too dilute samples can result in 
clear drops. Precipitate and clear drops are typical crystallization screen 
results for reagent conditions which do not promote crystallization and are 
part of every crystallization screen. However, by optimizing protein 
concentration for the screen, the number of clear and precipitated results can 
often be reduced, which in turn results in more efficient sample utilization 
while at the same time enhancing the chances for crystallization. The ideal 
concentration to crystallize the target protein can be determined by using PCT 
kit (Hampton research) according to the manufacturers’ protocol.  
2.18 Protein crystallization and optimization 
Different commercially available crystallization screens were used to screen 
initial conditions of crystallization, such as Index (Hampton Research), JCSG+ 
(Qiagen) and Wizard I+II (Emerald Biosciences). Manually, this experiment 
was carried out using the sitting drop diffusion method in 96-well plates 
following standard procedures. Alternatively, a nano-drop crystallization robot 
(Cartesian HoneyBee, Genomic Solutions), as part of the Hamilton-Thermo 
Rhombix system, was used to set-up crystal plates. The main advantage of 
using a robot is the smaller amount of protein needed for plates (150 or 300 nl 
per drop). All the crystallization plates were kept at room temperature. The 
initial crystallization hits needed to be optimized to get better quality crystals. 
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Optimization is based on varying the concentration of salt, protein and 
precipitant in the screen.  
2.19 X-ray data collection of crystals 
Using 10-30% (v/v) glycerol in the crystallization buffer, the crystals of target 
proteins were cryoprotected. A suitable protein crystal was picked out from 
the drops with a crystal loop and transferred to 5 µl cryoprotectant drop. Then 
the crystal was re-looped and mounted onto X-ray at 100K in-house using a 
Rigaku/MSC MicroMax-007HF rotating anode equipped with a Saturn 944+ 
CCD detector at wavelength 1.54178 Å. For higher resolution data, crystals 
were taken to the European Synchrotron Radiation Facility (ESRF), France. 
2.20 Heavy metal soaking of VC1805 crystal 
In order to obtain heavy-metal derivatives, crystals were soaked at different 
metal solution concentrations (1 mM/ 5 mM/ 10 mM/ 15mM/ 20mM) for 
different time intervals (10 min/ 30min/ 16 h). Heavy metals such as platinum 
potassium cyanide, K2PtCN4; potassium aurocyanide, KAu(CN)2; ytterbium 
sulphate, Yb2(SO4)3; samarium acetate hydrate, Sm(C2H3O2)3.H2O; mercury 
nitrate, Hg(NO3)2; p-chloromercuri benzene sulphonate (PCMBS), 
C6H5O3HgS; were used for soaking. Next, the crystals were cryoprotected in 
preparation for data collection.  
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2.21 C1q binding assay 
Using a 96-well microtitre plate (Maxisorb, NUNC, Denmark), wells were 
coated with 50 µL of a two-fold serial dilution of VC1805 in PBS (phosphate 
buffered saline), which was in range of 4 µg/mL to 0.125 µg/mL. For negative 
controls, wells were also coated with 50 µL of a two-fold and five-fold dilution 
of milk in PBS buffer, and with 50 µL of the archaeal DNA-binding protein 
hssb1 at 4 and 2 µg/mL, diluted in PBS buffer. Coating was done overnight at 
4 °C. The protein Hsbb1 (which, like C1q is highly positively charged) and milk 
(which is a mixture of different proteins) were used as negative controls in this 
experiment. The wells were then washed four times with PBS + 0.1 % Tween 
20 (Buffer A). The remaining protein binding sites on the wells were saturated 
with 360 µL of blocking buffer (10% milk in PBS) and incubated for 1 h at 
room temperature, then wells were washed four times with buffer A. 50 µL of 
blocking buffer containing 5 µg C1q was added to the wells and incubated at 
37°C for 1 h followed by washing four times with buffer A. 100 µl biotinylated 
anti- human C1q IgG in blocking buffer which contained 5 µg of antibody were 
added to the wells and incubated at 37 °C for 1 h. After incubation, the wells 
were washed four times with Buffer A. Streptavidin HRP (horseradish 
peroxidase, KPL Inc.) was added to the wells and incubated at 37 °C for 1 h, 
followed by four washes with buffer A. 100 µL of TMB peroxide substrate 
(prepared as per manufacturer’s instructions, KPL) was added to the wells 
and kept at room temperature. As a positive control for C1q binding, wells 
were coated with hen ovalbumin, and then reacted with rabbit-anti-hen 
ovalbumin antiserum, to form immune complexes in the wells. C1q was 
purified from Human plasma (Scipac Ltd.) (Salvador-Morales et al., 2006). 
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Rabbit anti-C1q IgG was biotinylated with biotin N-hydroxysuccinimide.  
2.22 Complement consumption assay 
NUNC Maxisorp 96-well microtitre plate wells were coated with 100 µL (5 µg) 
of VC1805 in PBS. As a positive control, wells on the same plate were coated 
with 100 µL per well of 100 µg/mL hen ovalbumin (Sigma) in 0.1 M sodium 
carbonate buffer, pH 9.6. The plate was incubated overnight at 4°C, then 
washed 4 times with buffer A. The remaining sites for protein binding on the 
plate were saturated by blocking buffer and incubated for 1 h at room 
temperature before again washing 4 times with buffer A. Rabbit anti-
ovalbumin antiserum, prepared by MRC Immunochemistry Unit in Oxford, was 
heat-treated for 30 min at 56 °C to inactivate rabbit C1q, followed by ten-fold 
dilution in PBS and 100 µL was added to the ovalbumin-coated wells and 
incubated for 1 h at room temperature. Wells were washed 4 times with buffer 
A. The plates were now ready for the complement consumption assay. 
Reagent and buffer details were as previously described (Salvador-Morales et 
al., 2006). NHS (normal human serum) was diluted with 1 volume of DGBV++ 
buffer (dextrose-gelatin-verenal buffer). The diluted serum (300 µL) was 
added in triplicate to wells coated with VC1805, ovalbumin anti-ovalbumin and 
non-coated wells followed by incubation at 37 °C for 30 min. Serum was 
removed from wells and kept on ice until ready to assay for total complement 
haemolytic activity (Salvador-Morales et al., 2006). Briefly, serial 2-fold 
dilutions of serum were incubated with antibody-sensitised sheep erythrocytes 
and the degree of lysis determined after 1 h incubation at 37°C. The dilution of 
serum required to give 50% lysis was calculated.  
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2.23 Gene knockout 
2.23.1 Preparation of electrocompetent DH5α λpir strain  
E. coli DH5α λpir strain from -70˚C stock was streaked on LB agar plate. A 
single colony of DH5α λpir was inoculated into a flask containing 50 mL LB 
medium followed by the incubation of the culture at 37˚C overnight with 
shaking at 250 rpm. Next day, 500 mL of prewarmed LB medium in separate 
2 L flasks was inoculated with 25 mL of the overnight bacterial culture. The 
flasks were incubated at 37˚C with shaking at 250 rpm until the OD600 was 
about 0.35-0.4. This density is usually achieved after around 2.5 h. The 
culture was then rapidly transferred into an ice-water bath for 15-30 min. The 
culture was swirled occasionally to make sure that cooling occurred evenly. 
For maximum efficiency of transformation, the temperature was not allowed to 
exceed 4˚C at any stage in this procedure. The culture was transferred to pre-
chilled centrifuged bottles (kept at -20˚C) and harvested by centrifugation at 
2500 rpm for 20 min at 4˚C. The supernatant was discarded and the pellet 
was resuspended in 500 mL sterilized ice-cold water. Then, the cells were 
harvested again by centrifugation at 2500 rpm for 20 min at 4˚C. The 
supernatant was discarded and the pellet was resuspended in 250 mL 
sterilized ice-cold water containing 10% (v/v) glycerol. Again, the cells were 
harvested by centrifugation at 2500 rpm for 20 min at 4˚C. The supernatant 
was carefully discarded to remove any remaining drops of buffer. Finally, the 
pellet was resuspended in 1 mL sterilized ice-cold GYT medium (10% (v/v) 
glycerol, 0.125% (w/v) yeast extract, 0.25% (w/v) tryptone) by gentle swirling 
rather than vortexing and pipetting. The cell suspension was diluted to a 
concentration of 1 X 1010 cells/mL (1.0 OD600 = ~2.5 X 108 cells/mL) with ice-
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cold GYT medium. 50 µL of cells were used for each transformation. For 
storage, 50 µL aliquots of the cell suspension was dispensed into sterile (ice-
cold) 0.5 mL eppendorfs and flash-frozen with liquid nitrogen before 
transferral to - 70˚C.  
2.23.2 Preparation of electrocompetent Vibrio cholerae  
V. cholerae electrocompetent cells were prepared and electroporated as 
described by the published procedure with minor some modifications (Marcus 
et al., 1990). V. cholerae  O1 El Tor strain N16961 (Streptomycin resistant) 
from a -70˚C stock were streaked onto LB agar media containing 200 µg/mL 
streptomycin followed by overnight culture of V. cholerae in 50 mL LB broth 
with 200 µg/mL streptomycin. Using a 2% inoculums of overnight culture in 
300 mL LB broth containing 200 µg/mL streptomycin, cells were grown until 
the OD600 reached about 0.4. After incubation, cultures were split into 50 mL 
falcon tubes and pelleted by centrifugation at 4000 rpm for 15 min at 4˚C. The 
supernatant was discarded and the pellet was washed three times with 
250 mL of 10% (v/v) glycerol containing 272 mM sucrose. Sucrose/ glucose is 
not suitable for autoclaving so it was sterilized by using 0.22 µm filter.  Finally, 
the cells were resuspended with 10% (v/v) glycerol containing 272 mM 
sucrose to make 1 X 1010 cells/mL. This electrocompetent V. cholerae was 
stored at -70˚C in 50 µL aliquots for future use after flash-freezing with liquid 
nitrogen.  
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2.23.3 SOE-PCR (Splicing by Overlapping Extension PCR) 
PCR has been carried out to amplify portions at the beginning and the end of 
gene of the interest to be knocked out (AB and CD) (Figure 2.5). Primers were 
commercially synthesized (Table 2.3) and purchased from IDT, USA. PCRs 
were performed in a volume of 50 µL containing 1.5 µL of forward primer 
(25µM), 1.5 µL of reverse primer (25 µM), 5 µL PCR buffer (10X), 1 µL 
template genomic DNA of V. cholerae O1 El Tor strain N16961 (80 ng), 2 µL 
dNTPs (10 mM), 1 µL Taq DNA polymerase and 38 µL water. The 
amplification conditions were the same as the standard PCR described earlier 
(Section 2.4). Use of Taq DNA polymerase in PCR gives 3´ A-overhangs 
which is suitable for further cloning into pTOPO vector. The PCR products 
were run on agarose gel. The product bands was excised from the gel and 
purified by the protocol given in the QIAquick Gel Extraction Kit (QIAGEN).  
2.23.4 PCR to ligate beginning and end of gene 
1 µL of each construct (40 ng each) was used as template per reaction. The 
same SOE-PCR reaction as described above was carried out until the 4th 
cycle without primer (Figure 2.5). The primers (A and D) were added after the 
4th cycle (allowing overhang in constructs to anneal) and the PCR was 
continued for another 26 cycle according to the standard protocol described 
earlier. Agarose gel electrophoresis and gel extraction of PCR products was 
done (Section 2.5).  
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Table 2.3 Primers used in Gene knockout  
Target 
protein 
Primer 
name 
Primer sequence 
(5′- 3′) 
M050809F_A ctgagctcagcaatggctg 
M050809R_B ggctggctaccaatgcaag 
M050809F_C cttgcattggtagccagcccggcagttcaacacgagtc 
M050809R_D gaagtgaatgccgcagcag 
M050809F_E ccacaatgacttcatcgagg 
VC050809 
M050809R_F cctaccattgattccgacag 
M180405F_A caatctaagcgggatcgatc 
M180405R_B ctggtaacaccaacggttag 
M180405F_C ctaaccgttggtgttaccagcggatggaatcctatcgtag 
M180405R_D gttgaatctaacgagttgcga 
M180405F_E gcggtgatattgccacaatc 
VC050809 
M180405R_F gatgagtctcaatggtgttcc 
 
 
 
 
 
 
 
 
 
Figure 2.5 SOE-PCR (Splicing by Overlapping Extension PCR) 
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2.23.5 Cloning into pCR 2.1 –TOPO vector 
TOPO cloning reactions were setup in 6 µL of reaction mixture consisting of 
50 ng of insert (ABCD in Figure 2.5), 1 µL supplied salt solution (Invitrogen), 
1 µL TOPO vector and water to a total volume of 5 µL. The reaction was 
mixed gently and incubated for 15 to 20 min at room temperature (22 °C) and 
placed on ice. 2 µL of the TOPO cloning reaction was transformed into 
chemically competent One Shot TOP10F´ E. coli cells using the standard 
protocol supplied by Invitrogen. Finally, positive clones were selected by 
blue/white colony screen followed by colony PCR (Section 2.10.1) using A 
and D primers.  
2.23.6 Construction of pADS132 vector with multiple cloning sites 
To get suitable cloning sites in the pDS132 suicide vector (Philippe et al., 
2004) for our gene of interest, new MCS were introduced (XbaI- NdeI- NsiI- 
XhoI- NheI- PstI- SpeI- SacI) and the modified vector was named pADS132. A 
forward (5′- gctctagacatatgatgcatctcgaggctagcctgcagactagtgagctcag -3′) and 
a reverse  (5′- ctgagctcactagtctgcaggctagcctcgagatgcatcatatgtctagagc -3′) 
primer were commercially synthesized and purchased (IDT, USA). The 
synthesized fragments were annealed (80 °C for 10 min followed cooling it 
down to room temperature), digested with XbaI and SacI and ligated with 
similarly digested pADS132 according to the protocol described earlier 
(Section 2.6 and 2.7). The new suicide vector pADS132 contains unique XhoI 
and NcoI sites which was confirmed by double digestion (Figure 2.6). DNA 
sequencing also confirmed the presence of the MCS in pADS132. 
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Figure 2.6 Construction of pADS132 vector 
M, 1 kb DNA ladder (NEB, USA); lane 1, circular pADS132 vector; lane 2, 
double digest (XhoI and NcoI) of pADS132 results two linear bands; lane 3, 
single digest of pADS132 by XhoI; lane 4, single digest of pADS132 by NcoI. 
2.23.7 cloning of genes of interest in pADS132  
SOE-PCR product cloned into pCR 2.1 –TOPO vector was digested with XhoI 
and SpeI and ligated to similarly digested pADS132 vector. The ligation 
reactions were transformed by electroporation into E. coli DH5α λpir strains to 
allow replication of the vector. Briefly, 5 µl of ligation reaction (50 ng) was 
electroporated in 50 µl cells of DH5α λpir which contain 5 X 108 cells. 
Electroporation was carried out with an Eppendorf 2510 electroporator with 
the pulse controller set at 10 µF, 900 V and 600 Ω. After electroporation, 
900 µL LB medium was added to the suspension and the tube was placed 
horizontally in a shaking incubator for 1 h at 37 °C and cells were plated onto 
LB agar containing 34 µg/mL chloramphenicol. Positive clones were identified 
by colony PCR using A and D primers. 
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2.23.8 Electroporation of vector in V. cholerae  
50 ng of vector DNA of pADS132 containing the gene of interest was 
electroporated into 50 µL of electrocompetent V. cholerae  O1 El Tor strain 
N16961 containing 5 X 108 cells. Electroporation was carried out with a 
Eppendorf Electroporator 2510 using cuvettes with a 0.2 cm gap distance and 
settings of 10 µF, 830 V and 600 Ω. After electroporation, the suspension was 
diluted with 900 µL LB medium, placed horizontally in a shaking incubator for 
1 h at 37 °C and plated on LB agar containing 34 µg/mL chloramphenicol and 
200 µg/mL streptomycin. 
2.23.9 Colony PCR to screen single crossover  
Colonies of V. cholerae  O1 El Tor strain N16961 containing the correct insert 
were identified using colony PCR screening. Colonies were randomly picked 
by sterile tips and incubated overnight at 37 °C in 5 mL LB with 34 µg/mL 
chloramphenicol and 200 µg/mL streptomycin. Colony PCR was performed 
with corresponding internal primers A and D and flanking primers E and F. 
Glycerol stocks were made for positive single crossover colonies. 
2.23.10 Select for double crossover mutant by sucrose sensitivity  
Single crossover positive colonies were incubated overnight in 5 mL LB broth 
with 200 µg/mL streptomycin and without chloramphenicol. Next day, 100 µL 
of 10-2 to 10-7 serially diluted cultures were plated on LB containing 10% 
sucrose and incubated at 30°C overnight. After incubation, single colonies 
were picked and streaked on a plate of LB containing 10% sucrose and 
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200 µg/mL streptomycin; LB containing 34 µg/mL chloramphenicol; and 5 mL 
LB with 200 µg/mL streptomycin; followed by incubation at 30 °C overnight. 
Plates were divided into 8 sections with one section used per single colony.  
2.24 Characterization of VcFur 
2.24.1 Electrophoretic mobility shift assay (EMSA) 
The fur promoter of gene locus vc2694 was chosen for the gel-shift assays, 
based on a study of fur promoters in V. cholerae (Mey et al., 2005), with 
forward and reverse oligonucleotides purchased from VHBIO, with one oligo 
labeled with FITC (fluorescein isothiocyanate). The oligonucleotide was 5′-
ATTGATAATGATTATTATTAAC, where the 19-bp Fur-box is underlined. 
Working solutions containing 2 µM of forward and reverse oligos were 
prepared in buffer (20 mM MES pH 6.5, 1 mM DTT). Eppendorfs containing 
the oligo mix were placed into a water bath at 80-85 °C then allowed to cool 
down at room temperature for 2 h. The resultant double stranded DNA duplex 
was stored at -20 °C. To prepare acrylamide gels, 5 mL of Accuflow 
acrylamide, 2 mL of 10X TBE (Tris-borate-EDTA) buffer or 10X TB (Tris-
borate) buffer, 18 mL of deionised water, 20 µL of TEMED 
(tetramethylethylenediamine), 100 µL of 10% ammonium persulphate were 
mixed together and poured between the glass plates with comb inserted. After 
drying, the gels were always pre-run for 10 min at 200 V with appropriate 
running buffer before loading samples. 
The DNA mobility shift assay was performed using the published method with 
minor modifications (Ochsner et al., 1995). A final concentration of 50 nM 
FITC-labeled double stranded DNA fragment was mixed into 20 µL binding 
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buffer which containing 10 mM bis-Tris borate (pH 7.5), 40 mM KCl, 
0.1 mg/mL of bovine serum albumin (BSA) (Sigma fraction V) and 10% (v/v) 
glycerol. Different concentrations of native VcFur were added and the mixture 
was incubated at 37 °C for 15 min using a static incubator. For the negative 
control, 50 nM FITC-labeled double stranded DNA (poly A and poly T) was 
used.  2 µL of 10X Ficoll loading dye was added to the samples and 10 µL of 
each samples was loaded into gel wells running at 60 V constant voltage. The 
gel was run at 10 mA constant current for 80 min in running buffer (20 mM 
bis-Tris borate and 0.1 mM MnSO4 or 20 mM bis-Tris borate only). After the 
run, the gel was scanned at 473 nm using Fujifilm FLA-5000 series scanner. 
2.24.2 Metal binding studies of VcFur 
Two batches of VcFur were purified into a final buffer containing 20 mM 
HEPES, 200 mM NaCl and 10% (v/v) glycerol at pH 7.5. Batch 1, was 
dialyzed in 20 mM HEPES, 200 mM NaCl, 1 mM ZnCl2 and 2 mM DTT and 
10% (v/v) glycerol, followed by removal of excess metal ion by dialysis of 
protein samples in the same buffer without ZnCl2. Batch 2 was not dialysed 
against any zinc-containing buffer. Finally both samples were dialysed 
overnight at 4 °C against 20 mM HEPES, 20 mM NaCl and 5% (v/v) glycerol 
at pH 7.5. The concentration of protein was measured using a NanoDrop 
spectrophotometer (Thermo Scientific). 
 2.24.3 Removal of metals from VcFur 
To remove metal ions (mainly Zn) from VcFur, the experiment was carried out 
with minor modification as previously described (Althaus et al., 1999). 50 µM 
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of both batches of VcFur were dialysed overnight against 200 mM EDTA, 
20 mM HEPES, 20 mM NaCl and 5% (v/v) glycerol at pH 8.0. To remove 
extra EDTA, the samples were dialysed in the same buffer without EDTA for 3 
h followed by dialysis into 20 mM HEPES, 20 mM NaCl and 5% (v/v) glycerol 
at pH 7.5 with 3 buffer changes. All the procedures were carried out at 4 °C. 
2.24.4 Addition of metals into EDTA-treated VcFur 
Different metals Zn(II) (as ZnCl2), Mn(II) (as MnSO4) and Fe(III) (as FeCl3) 
were added into EDTA-treated VcFur. The procedure for addition of metal into 
VcFur was followed with minor modifications (Mills and Marletta, 2005). To 
incorporate Zn(II), 50 µM of VcFur was dialysed overnight with 3 equivalent of 
ZnCl2 (150 µM at pH 6.2) in 20 mM HEPES, 50 mM NaCl and 5% (v/v) 
glycerol at pH 6.2 in the presence of a 20-fold excess of DTT. For Mn(II), 50 
µM of VcFur was dialysed overnight with 4 equivalent of MnSO4 (200 µM) in 
20 mM HEPES, 50 mM NaCl and 5% (v/v) glycerol at pH 7.5. For the 
incorporation of the Fe (III), ferric chloride (FeCl3) was first dissolved with a 
10-fold excess of citric acid which was adjusted to pH 7.0 and 50 µM of VcFur 
was dialysed overnight with 3 equivalent of FeCl3 (150 µM) in 20 mM HEPES, 
50 mM NaCl and 5% (v/v) glycerol at pH 7.0. To remove the excess metal, all 
samples were dialysed in 20 mM HEPES, 20 mM NaCl and 5% (v/v) glycerol 
at pH 7.5, without adding metal salts for 4 h followed by 3 buffer changes. 
2.24.5 Analysis of metals 
The metal contents of the proteins were analyzed using inductively coupled 
plasma mass spectrometry (ICP-MS) at the University of Edinburgh. All the 
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samples which were subject to metal analysis were finally dialysed against a 
buffer containing 20 mM HEPES, 20 mM NaCl and 5% (v/v) glycerol at pH 7.5 
and the machine was equilibrated with the same buffer to minimize any metal 
contamination from the buffer itself. Standard metal solutions were measured 
between every sample measurement to maintain higher sensitivity. 
Measurements were carried out in triplicate. 
2.24.6 Spin labeling of VcFur 
Spin labeling of VcFur was carried out in 2.5 mL of reaction mixtures 
containing 20 µM of protein, 100 µM of spin labeling reagent, MTSL (1-oxyl-
2,2,5,5-tetramethyl-∆3-pyrroline-3 methyl-methanethiosulfonate), and a buffer 
X (20 mM HEPES, 200 mM NaCl at pH 7.5 ) to a final volume of 2.5 mL 
followed by incubation at 4°C for 1 h. Next, the unbound spin label (MTSL) 
from the sample was removed by gel filtration using Sephadex G-25 
minicolumns PD-10 (Amersham Biosciences). Briefly, the column was 
equilibrated with 25 mL elution buffer (buffer X) and the flow-through was 
discarded. Next, 2.5 mL of reaction mixture was loaded onto the column and 
the flow-through was discarded. The proteins in the column eluted with 8 mL 
of buffer and the first 8 fractions of 0.5 mL each and the next 4 fractions of 
1 mL each were collected. The appropriate fractions, confirmed by Bradford 
protein assay, were pooled and concentrated to 200 µL. Then, 1 mL of buffer 
X prepared in D2O (deuterium oxide) was added into the concentrator and the 
sample was concentrated again to 200 µL. This process was repeated three 
times and finally 40-50% deuterated ethylene glycol was added to the sample 
to obtain a final concentration of 100 µM protein sample in 100 µL. 
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Structural determination of VC0508, VC0509, VC1804 and VC1805 
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3. Structural determination of VC0508, VC0509, VC1804 and VC1805 
This chapter describes the results of cloning, expression, purification and 
structural determination of VC0508, VC0509, VC1804 and VC1805. All the 
structures were determined by X-ray crystallography except VC1804 which 
was not soluble. The first helix of VC1804 is missing compared to VC0508, 
VC0509 and VC1805 and may be required for solubility in E. coli. All the 
structures show similar folds, as predicted from the sequence analyses. 
However, the only structural homologue of these proteins is human p32 which 
is a versatile protein and can bind to several other proteins. 
3.1 Overview of VC0508, VC0509, VC1804 and VC1805 
VC0508, VC0509, VC1804 and VC1805 are hypothetical proteins of 
V. cholerae O1 El Tor strain N16961 that contain 147, 147, 104, 148 amino 
acid residues respectively. The molecular weights of VC0508, VC0509, 
VC1804 and VC1805 proteins are 17, 17.1 12.3 and 16.8 kDa and their 
calculated isoelectric points (pI) are 5.0, 5.2, 5.4 and 4.7, respectively. 
Sequence analyses of these proteins did not suggest any structural 
homologues in the existing protein structure database.  
3.2 Cloning 
3.2.1 vc0508 gene 
Amplification of the vc0508 gene was carried out by PCR from genomic DNA 
of V. cholerae O1 El Tor strain N16961 using standard protocols 
(Figure 3.1.A) (Section 2.4). Primers (VHBIO, UK) for PCR amplification from 
genomic DNA contained specific recognition sites NcoI in the forward primer 
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(5′- GGACTCACCATGGCCAAATTAAC -3′) and SalI site in the reverse 
primer (5′- GAAGGGAAGTCGACAGTTATTGC -3′). The forward primer 
introduced a Ser2Ala mutation after the start codon of the VC0508 protein. 
After amplification, the PCR product was digested with NcoI and SalI 
enzymes and cloned into the similarly digested pLou3 expression vector 
(Section 2.6 and 2.7). After propagation in E. coli DH5α strain, the positive 
clones were picked up by blue/white screening due to the presence of lacZα 
complementation gene in pLou3 vector. Positive clones were verified by 
double digestion (Figure 3.1.B) (Section 2.10.2) and DNA sequencing in the 
University of Dundee (Section 2.10.3). 
 
 
 
 
 
 
Figure 3.1 Agarose gel electrophoresis of vc0508 gene products 
(A) Amplification of vc0508 gene from genomic DNA of V. cholerae O1 El Tor 
strain N16961. M, 1 kb DNA ladder (Promega); lane 1, Amplification of 
vc0508 gene products. (B) Double digestion of cloning vector pLou3 
containing vc0508 gene. Lane 1 (bottom band), insert vc0508 gene fragment; 
lane 1 (top band), linear pLou3 vector without insert gene after double 
digestion. 
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3.2.2 vc0509 gene 
V. cholerae O1 El Tor strain N16961 strain was used in the amplification of 
the vc0509 gene by PCR from genomic DNA using standard protocols (Figure 
3.2.A). Primers (VHBIO, UK) for PCR amplification from genomic DNA 
contained specific recognition sites NcoI in the forward primer (5′-
 CTGAAAGGCCATGGTTATGATTG -3′) and SalI site in the reverse primer 
(5′- GAGAGAGTCGACTTTAGTTGAAC -3′). After amplification, the PCR 
product was digested with NcoI and SalI enzymes and cloned into the 
similarly digested pLou3 expression vector. Positive clones were identified by 
blue/white screening followed by double digestion Figure 3.2.B) and DNA 
sequencing. 
 
 
 
 
 
 
Figure 3.2 Agarose gel electrophoresis of vc0509 gene products 
(A) Amplification of vc0509 gene from genomic DNA of V. cholerae O1 El Tor 
strain N16961. M, 1 kb DNA ladder (Promega); lane 1, Amplification of 
vc0509 gene products. (B) Double digestion of cloning vector pLou3 
containing vc0509 gene. Lane 1 (bottom band), insert vc0509 gene fragment; 
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lane 1 (top band), linear pLou3 vector without insert gene after double 
digestion. 
3.2.3 vc1804 gene 
Standard PCR protocol was used to amplify vc1804 gene by PCR from 
genomic DNA of V. cholerae O1 El Tor strain N16961 (Figure 3.3.A). Primers 
(VHBIO, UK) for PCR amplification from genomic DNA contained specific 
recognition sites NcoI in the forward primer (5′- 
CCAATCCATTATTACCATGGTTCT -3′) and SalI site in the reverse primer 
(5′- GAATCGCGTCGACTTAGCGAAT -3′). The amplified PCR product was 
digested with NcoI and SalI enzymes and cloned into the similarly digested 
pLou3 expression vector After propagation in E. coli DH5α, Positive clones 
were identified by blue/white screening followed by double digestion 
(Figure 3.3.B) and DNA sequencing. 
Another construct of vc1804 gene was made using the pEHISTEV vector (Liu 
and Naismith, 2009). The vc1804 gene was amplified by PCR from genomic 
DNA of V. cholerae O1 El Tor strain N16961. Primers (VHBIO, UK) for PCR 
amplification contained specific recognition sites NcoI in the forward primer 
(5′- GCCAATCCATTATTACCATGGTTCTATAC -3′) and EcoRI site in the 
reverse primer (5′- GAAGAATCGAATTCGGTTAGCGAATCATG -3′). After 
amplification, the PCR product was digested with NcoI and EcoRI enzymes 
and cloned into the similarly digested pEHISTEV vector. After propagation in 
E. coli DH5α, the positive clones were verified by colony PCR (Section 3.10.1) 
followed by DNA sequencing. 
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Figure 3.3 Agarose gel electrophoresis of vc1804 gene products 
(A) Amplification of vc1804 gene from genomic DNA of V. cholerae O1 El Tor 
strain N16961. M, 1 kb DNA ladder (Promega); lane 1, Amplification of 
vc1804 gene products. (B) Double digestion of cloning vector pLou3 
containing vc1804 gene. Lane 1 (bottom band), insert vc1804 gene fragment; 
lane 1 (top band), linear pLou3 vector without insert gene after double 
digestion. 
3.2.4 vc1805 gene 
The vc1805 gene was amplified by PCR from genomic DNA of V. cholerae O1 
El Tor strain N16961 (Figure 3.4.A). The forward primer containing the 
specific recognition site NcoI (5′-GGAGGCATAACCATGGCTAACATTTTG -
3′) and reverse primer containing the specific recognition site EcoRI (5′-
CTTGATGGAATTCACTAAGGAGCCGAG -3′), were purchased from VHBIO, 
UK. After amplification, the PCR product was digested with NcoI and EcoRI 
enzymes and cloned into the similarly digested pEHISTEV vector. After 
propagation in E. coli DH5α, the positive clones were verified by colony PCR 
(Figure 3.4.B) and DNA sequencing. 
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Figure 3.4 Agarose gel electrophoresis of vc1805 gene products 
(A) Amplification of vc1805 gene from genomic DNA of V. cholerae O1 El Tor 
strain N16961. M, 1 kb DNA ladder (Promega); lane 1, Amplification of 
vc1805 gene products. (B) Colony PCR of cloning vector pEHISTEV 
containing vc1805 gene. Lane 1, colony PCR products of pEHISTEV vector 
containing vc1805 gene (indicated by red asterisk). 
3.3 Protein expression, optimization of solubility and purification 
3.3.1 VC0508 protein 
The E. coli K12 strain TB1 (DE3), was used to transform the expression 
vector pLou3 containing the vc0508 gene using standard methods (Section 
2.8). The best soluble protein expressions were achieved in TPB medium and 
the condition was 25 °C overnight incubation for 24 h with the addition of 
0.5 mM IPTG (Section 2.13). These conditions were also used to scale up 
recombinant VC0508 protein expression in a 5 L culture.  
The cell pellet was resuspended in buffer A (50 mM HEPES, 500 mM NaCl, 
10 mM imidazole and 10% (v/v) glycerol) containing DNase and EDTA free 
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protease inhibitor cocktail and sonicated. After centrifugation, the soluble 
fragment was syringe filtered through a 0.22 µm filter unit  and loaded on to a 
HisTrap™ HP column (Ni2+-affinity column, GE Healthcare), to purify the target 
proteins. His-tagged proteins bound to the HisTrap™ HP column were eluted 
by a higher imidazole concentration buffer. Fractions were analysed by SDS-
PAGE and pooled (Figure 3.5.A). 
To remove the extra imidazole, pooled samples were dialysed for several h 
against 4 L of buffer A and 1 mM DTT at 4 °C, with two buffer changes. TEV 
protease was added into the dialysis tube containing 6X his-tagged protein 
(1 µg protease for 1 mg at 25 °C overnight). Digestion of protein sample was 
analyzed by SDS-PAGE to check the efficiency of TEV protease digestion 
(Figure 3.5.B). After TEV digestion, protein samples were syringe filtered 
through a 0.22 µm filter unit and loaded into the HisTrap™ HP column as 
before and the flow-through was collected in fractions and analyzed by SDS-
PAGE (Figure 3.5.C).  Corresponding fractions containing HMBP- cleaved 
target protein were pooled and dialysed against 4 L of buffer containing buffer 
A and 1 mM DTT overnight at 4 °C. After dialysis, the samples were then 
concentrated to 4.5 mL by using a 10,000-Da MWCO centrifugal concentrator 
(Sigma- Aldrich). Up to 4.5 mL of concentrated samples were loaded onto a 
Hiprep 16/60 Sephacryl S-200 gel filtration column (GE Healthcare) and 
eluted in buffer A and 1 mM DTT. Corresponding fractions of VC0508 were 
identified by chomatogram (Figure 3.5.E) and confirmed by SDS-PAGE 
(Figure 3.5.D).  For crystallization trials, fractions containing VC0508 were 
pooled and dialysed overnight at 4 °C against 4 L of buffer containing 10 mM 
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HEPES, 50 mM NaCl and 5% (v/v) glycerol. Purified proteins of VC0508 were 
analyzed by mass spectrometry which confirmed the expressions of the target 
proteins (Figure 3.5.F). 
 
 
 
 
 
 
 
 
 
Figure 3.5 Expression and purification of VC0508 protein 
(A) First Ni2+-affinity column pull down. M, protein marker (Mark12™, 
Invitrogen); lane 1, cell lysate after IPTG induction; lane 2, supernatant after 
sonication; lane 3, flow-through (unbound protein) after loading sample on to 
the column; lane 4-6, column wash with the buffer containing 10 mM 
imidazole; lane 7-9, elution in buffer containing 350 mM imidazole. Bands 
indicated by the red asterisks are MBP-fused VC0508. (B) TEV cleavage of 
his-tagged VC0508. Lane 1, dialysed eluted protein from first Ni2+-affinity 
column; lane 2, TEV digested sample of VC0508. (C) Second Ni2+-affinity 
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column. Lane 1, filtered TEV digested sample; lane 2, VC0508 without HMBP 
(D) Eluted VC0508 after gel filtration chromatography. Lane 1-4, fractions 
containing VC0508 protein. (E) Gel filtration peak corresponding to purified 
VC0508. (F) Matched peptides of VC0508 identified by mass spectrometry. 
 
3.3.2 VC0509 protein 
The expression vector pLou3 containing the vc0509 gene was transformed in 
E. coli K12 strain TB1 using standard methods (Section 2.8). The best soluble 
protein expressions were achieved in TPB medium and the condition was 
25 °C overnight incubation for 24 h with the addition of 0.5 mM IPTG 
(Section 2.13). Using these conditions, expression, optimization of solubility 
and purification of the protein VC0509 was done according to the procedure 
described earlier (Section 3.3.1) (Figure 3.6). For crystallization trials, purified 
VC0509 was dialysed in buffer containing 10 mM HEPES, 50 mM NaCl and 
5% (v/v) glycerol. Purified VC0509 protein was analyzed by mass 
spectrometry which confirmed the expressions of the target protein 
(Figure 3.6.F). 
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Figure 3.6 Expression and purification of VC0509 protein 
(A) First Ni2+-affinity column pull down. M, protein marker (Mark12™, 
Invitrogen); lane 1, cell lysate after IPTG induction; lane 2, supernatant after 
sonication; lane 3, flow-through (unbound protein) after loading sample on to 
the column; lane 4-6, column wash with the buffer containing 10 mM 
imidazole; lane 7-9, elution in buffer containing 350 mM imidazole. Bands 
indicated by the red asterisks are MBP-fused VC0509. (B) TEV cleavage of 
his-tagged VC0509. Lane 1, dialysed eluted protein from first Ni2+-affinity 
column; lane 2, TEV digested sample of VC0509. (C) Second Ni2+-affinity 
column. Lane 1, filtered TEV digested sample; lane 2, VC0509 without HMBP 
(D) Eluted VC0509 after gel filtration chromatography. Lane 1-4, fractions 
containing VC0509 protein. (E) Gel filtration peak corresponding to purified 
VC0509. (F) Matched peptides of VC0509 identified by mass spectrometry. 
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3.3.3 VC1804 protein 
The vectors pLou3 and pEHISTEV containing the vc1804 gene were 
transformed into E. coli K12 strain TB1 and E. coli strain BL21 (DE3), 
respectively. The expression, optimization of solubility and purification was 
done according to the procedure described earlier (Section 3.3.1) 
(Figure 3.7.A-B). Over-expression of VC1804 protein was confirmed by mass 
spectrometry (Figure 3.7.C), but no soluble proteins were obtained 
(Figure 3.7.A-B). Cells were exposed to various IPTG concentrations (1 mM/ 
0.5 mM/ 0.1 mM) and temperatures (such as 37 °C/ 25 °C/ 16 °C), shock 
(heat shock/ cold shock), but unfortunately no soluble expression was 
obtained.  
 
 
 
 
 
Figure 3.7 Expression and identification of VC1804 protein 
(A) Over-expression of VC1804 in pEHISTEV vector. M, protein marker 
(Mark12™, Invitrogen); lane 1-2, cell lysate and soluble fraction at 37 °C 
induction; lane 3-4, cell lysate and soluble fraction at 37 °C induction with heat 
shock; lane 5-6, cell lysate and soluble fraction at 37 °C induction with cold 
shock; lane 7-8, cell lysate and soluble fraction at 25 °C induction; lane 9-10, 
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cell lysate and soluble fraction at 25 °C induction with heat shock; lane 11-12, 
cell lysate and soluble fraction at 25 °C induction with cold shock. (B) Over-
expression of VC1804 in pLou3 vector. Lane 1-2, cell lysate and soluble 
fraction at 37 °C induction; lane 3-4, cell lysate and soluble fraction at 25 °C 
induction, (C) Matched peptides of VC1804 identified by mass spectrometry. 
3.3.4 VC1805 protein 
The plasmid DNA containing the vc1805 gene was transformed into E. coli 
strain BL21 (DE3). The best soluble protein expression was achieved in LB 
medium and the condition was 25 °C overnight incubation for 24 h with the 
addition of 0.5 mM IPTG. These conditions were also used to scale up 
recombinant VC0508 protein to 5 L culture according to the procedure 
described earlier (Section 3.3.1) 
The cell pellet was resuspended in PBS buffer containing DNase and EDTA-
free protease inhibitor cocktail and sonicated. Cell lysate was syringe filtered 
through a 0.22 µm filter unit and VC1805 was purified using a HisTrap™ HP 
column, according to the manufacturer’s instruction manual. Higher 
concentrations of imidazole were used to elute His-tagged proteins bound to 
the HisTrap™ HP column. Fractions were analyzed by SDS-PAGE and pooled 
(Figure 3.8.A). Protein samples were dialysed against 3 L of PBS buffer 
containing 50 mM Tris-HCl pH 7.5, 0.5 mM EDTA, 1 mM DTT, 20 mM 
imidazole and 0.3 M NaCl for 4 h at 4 °C, with two buffer changes, to remove 
excess imidazole from protein sample. Next, TEV protease was added into 
the dialysis tube containing his-tagged protein at 25 °C overnight. Digestion of 
sample by TEV was analyzed by SDS-PAGE (Figure 3.8.B) and 
corresponding fractions were pooled. The digested sample was dialysed 
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against the same dialysis buffer without EDTA and DTT for 2 h at 4°C and the 
dialysis buffer was changed twice. Protein samples were syringe filtered and 
loaded onto the nickel column and the flow-through was collected in fractions 
and analysed by SDS-PAGE (Figure 3.8.C). The flow-through containing 
VC1805 was dialysed against 3 L of PBS buffer containing 50 mM Tris-HCl 
pH 7.5, 20 mM imidazole and 20 mM NaCl overnight at 4 °C. After dialysis, 
the samples were concentrated to 4.5 mL and loaded onto a gel filtration 
column. Fractions were collected based on the observed peak of gel filtration 
(Figure 3.8.E), also analysed by SDS-PAGE (Figure 3.8.D) and the correct 
identity confirmed by mass spectrometry (Figure 3.8.F). 
 
 
 
 
 
 
 
 
 
Figure 3.8 Expression and purification of VC1805 protein 
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(A) First Ni2+-affinity column pull down. M, protein marker (Mark12™, 
Invitrogen); lane 1, cell lysate after IPTG induction; lane 2, supernatant after 
sonication; lane 3, flow-through (unbound protein) after loading sample on to 
the column; lane 4-5, column wash with the buffer containing 10 mM 
imidazole; lane 6-9, elution in buffer containing 350 mM imidazole. Bands 
indicated by the red asterisks are His-tagged VC1805. (B) TEV cleavage of 
his-tagged VC1805. Lane 1, TEV digested sample of VC1805. (C) Second 
Ni2+-affinity column. Lane 1, VC1805 without his-tag (D) Eluted VC1805 after 
gel filtration chromatography. Lane 1-3, fractions containing VC1805 protein. 
(E) Gel filtration peak corresponding to purified VC1805. (F) Matched peptides 
of VC1805 identified by mass spectrometry. 
3.4 Crystallization, optimization and X-ray data collection of targets 
3.4.1 VC0508 protein 
The initial concentration of VC0508 for crystallization was 12 mg/mL, which 
was determined by the PCT kit. A total of six crystal screens were set up with 
two different concentrations which were 12 mg/mL and 6 mg/mL. The screens 
were: The PEGs, Ammonium salt, pH clear, JCSG+, Classics (Qiagen) and 
Wizard I and II (Emerald Biosciences). Crystal plates were initially set up 
using a nano-drop crystallization robot, with 300 nl of buffer and 300 nl of 
protein per drop. Initial hits were obtained in the JCSG+ screen (Well number 
91; 0.2 M ammonium sulfate, 0.1 M bis-TRIS pH 5.5 and 25 % w/v PEG 3350) 
(Figure 3.9.A). Further optimizations gave the best quality crystals in the 
original condition using 8 mg/mL of protein (Figure 3.9.B). Using 20% (v/v) 
glycerol in crystallization buffer, the crystal of VC0508 was cryoprotected and 
diffracted X-rays at 100K in-house using a Rigaku/MSC MicroMax-007HF 
rotating anode equipped with a Saturn 944+ CCD detector at wavelength 
1.54178 Å (Figure 3.9.C). 
 79 
 
 
 
 
 
 
 
 
 
Figure 3.9 VC0508 protein crystal and diffraction pattern 
(A) Initial hits in JCSG+ screen (well number 91; 0.2 M ammonium sulfate, 
0.1 M bis-TRIS pH 5.5 and 25 % w/v PEG 3350). (B) Optimized crystal, using 
the initial hit condition, containing 8 mg/mL of protein. (C) X-ray diffraction 
image of VC0508 protein crystal. The resolution of the outer circle is 1.9 Å. 
3.4.2 VC0509 protein 
After PCT, crystallization plates were set up using 12 mg/mL and 6 mg/mL of 
VC0509 protein by robot as described earlier (Section 3.4.1). The best initial 
hits were obtained in PEGs screen (well number 12; 0.2 M ammonium sulfate, 
0.1 M MES pH 6.5 and 25 % w/v PEG 2000 MME) (Figure 3.10.A). After 
optimization, good diffraction quality crystals were obtained using 7 mg/mL of 
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protein in the original condition (Figure 3.10.B). The crystals of VC0509 were 
cryoprotected using 20% (v/v) glycerol in crystallization buffer and diffracted 
X-rays at 100K in-house at wavelength of 1.54178 Å (Figure 3.10.B). 
 
 
 
  
 
 
 
Figure 3.10 VC0509 protein crystal and diffraction pattern 
(A) Initial hits PEGs screen (well number 12; 0.2 M ammonium sulfate, 0.1 M 
MES pH 6.5 and 25 % w/v PEG 2000 MME). (B) Optimized crystal, using the 
initial hit condition, containing 7 mg/mL of protein. (C) X-ray diffraction image 
VC0509 protein crystal. The resolution of the outer circle is 2.4 Å. 
3.4.3 VC1805 protein 
A pre-crystallization test, PCT, indicated the appropriate protein concentration 
(8 mg/mL) for crystallization screening. Three screens from Hampton 
research (Index, Crystal Screen and Crystal Screen 2) were used in initial 
crystallization trials of native VC1805. This experiment was carried out using 
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the sitting drop diffusion method following standard procedure supplied by the 
manufacturers. Crystals were observed in Index (33) (Figure 3.11.A) and 
Crystal Screen (41) (Figure 3.11.B). After optimization, the best quality 
crystals were obtained in 0.1 M HEPES-Na pH 7.5, 10% v/v 2-propanol, 24% 
w/v PEG 4,000 which is an optimization of condition 41 of Crystal Screen 
(Figure 3.11.C). Crystals were cryoprotected in crystallization buffer with 
20% (v/v) glycerol added before being flash-frozen in a nitrogen gas stream at 
100 K. X-ray data were collected on station ID14-1 of the European 
Synchrotron Radiation Facility (ESRF), Grenoble, France (Figure 3.11.D). 
 
 
 
 
 
 
 
 
Figure 3.11 VC1805 protein crystal and diffraction pattern 
(A) Initial hits in Index 33 (1.1 M sodium malonate pH 7.0, 0.1 M HEPES pH 
7.0, 0.5% v/v jeffamine ED-2001 ® pH 7.0). (B) Initial hits in Crystal screen 41 
(0.1 M HEPES-Na, pH 7.5, 10% v/v 2-propanol, 20% w/v PEG 4,000). 
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(C) Optimized crystal in 0.1 M HEPES-Na pH 7.5, 10% v/v 2-propanol, 24% 
w/v PEG 4000. (D) X-ray diffraction image of VC1805 optimized protein 
crystal. The resolution of the outer circle is 1.9 Å. 
3.5 Structure solution and refinement 
3.5.1 VC1805 crystal 
The native cryoprotected crystals diffracted to a maximum resolution of 
2.13 Å. The structure was solved by multiple heavy atom isomorphous 
replacement using data from a crystal soaked for 30 min in 5 mM mercury 
nitrate or 5 mM PCMBS and data were collected on station ID14-1 of the 
European Synchrotron Radiation Facility (ESRF), Grenoble, France. Data 
were indexed and integrated using the program MOSFLM (Leslie, 1992). The 
integrated data were merged and scaled using the programs of the CCP4 
(CCP4., 1994) suite. The initial phases were obtained using the program 
SOLVE (Terwilliger and Berendzen, 1999) with density modification using the 
program RESOLVE (Terwilliger, 2000, 2003a, b), confirming the space group 
as P3121. Manual model rebuilding and refinements were conducted using 
the programs O (Jones TA, 1991), COOT (Emsley and Cowtan, 2004) and 
REFMAC (Murshudov et al., 1997). The final model had an R-factor of 0.235 
and an Rfree of 0.316. Parts of the protein have missing electron density as 
they are highly disordered, possibly contributing to the higher Rfree. Part of the 
final 2Fo-Fc electron density map is shown in Figure 3.12. The data collection 
and refinement statistics for native and heavy atom derivatives are 
summarized in Table 3.1. Atomic coordinates and structure factors of VC1805 
have been deposited in the Protein Data Bank (PDB) with code 2v1l 
(www.rcsb.org). 
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Table 3.1 Data collection and refinement statistics of VC1805 crystal. 
Numbers in parentheses refer to highest resolution shell. 
Data collection Crystal (data collected at synchrotron) 
 Native Mercury Nitrate PCMBS 
Unit cell parameters (Å) 
Space group P3121 
a = b = 78.3 
c = 42.3 
a = b = 78.4 
c = 41.3 
a = b = 78.7 
c = 42.3 
Maximum resolution (Å) 2.13  
(2.19-2.13) 
2.9  
(3.06-2.9) 
2.3  
(2.42-2.3) 
Rmergea 0.057 (0.375) 0.079 (0.359) 0.038 (0.278) 
Observed reflections 75,489 17,207 35,617 
Unique reflections 8,549 3,223 6,496 
Completeness (%) 99.4 (99.4) 94.8 (94.8) 94.6 (96.7) 
<I/σI> 23.2 (6.4) 21.8 (5.3) 29.2 (4.6) 
Multiplicity 8.8 (9.0) 5.3 (5.3) 5.5 (4.7) 
No. of heavy atom sites  2 1 
<figure of merit > after SOLVE 0.43   
Refinement    
Resolution limits                 39.2-2.13   
Number of reflections            8131   
R factorb                          0.235   
Free R factorc                            0.316   
RMSD ideal bond length (Å) 0.013   
RMSD ideal bond angles (°) 1.39   
No. of protein atoms 1054   
No. of water atoms 35   
Average B-factor for protein (Å2) 39.2   
Average B-factor for water (Å2) 40.4   
 
aRmerge = ∑h∑ j| Ihj- 〈Ih〉|/∑h∑ j, where Ihj is the intensity of the jth observation of 
unique reflection h. 
bOverall R factor ∑h||Foh| - |Fch||/∑h|Foh| , where Foh and Fch are the observed and 
calculated structure factor amplitudes for reflection h. 
cFree R factor is equivalent to overall R factor , but is calculated using 5% of 
reflections excluded from the maximum-likelihood refinement stages. 
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Figure 3.12 Stereo view of 2Fo-Fc electron density map of VC1805. A region 
of the map is shown, contoured at 1σ. 2Fo-Fc refers to the difference between 
twice the observed structure factor amplitudes and the calculated amplitudes. 
This and other figures were created with PyMOL (DeLano, 2007). 
3.5.2 VC0508 crystal 
A cryoprotected crystal of VC0508 diffracted to 1.9 Å and the data were 
integrated and scaled by using the program HKL2000 (Otwinowski and Minor, 
1997) and the CCP4 (CCP4., 1994) suite. The spacegroup of the crystal was 
P21. Analysis of solvent content of VC0508 crystal, suggested two chains per 
asymmetric unit which gave 41% solvent content and a Matthews coefficient 
of 2.05 Å3/Da (Kantardjieff and Rupp, 2003; Matthews, 1968). An automated 
molecular replacement server BALBES (Long et al., 2008) was used to solve 
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the VC0508 structure using the VC1805 structure (PDB code 2v1l) as a 
search model confirming the spacegroup as P21. The search model has 59% 
sequence similarity to VC0508. The initial R-factor and Rfree were 0.337 and 
0.384, respectively. The partially built output model was completed manually 
using the program COOT (Emsley and Cowtan, 2004) followed by refinement 
using REFMAC (Murshudov et al., 1997) and PHENIX (Adams et al., 2002). 
The final R-factor was 0.227 and Rfree was 0.275. Part of the final 2Fo-Fc 
electron density map is shown in Figure 3.13. The statistics of data collection 
and refinement statistics are summarized in Table 3.2. Atomic coordinates 
and structure factors of VC0508 have been deposited in the PDB (2w56). 
 
 
 
 
 
 
 
 
 
 
Figure 3.13 Stereo view of 2Fo-Fc electron density map of VC0508. A region 
of the map is shown, contoured at 1σ.  
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Table 3.2 Data collection and refinement statistics of VC0508 crystal. 
Numbers in parentheses refer to highest resolution shell. 
 
aRmerge = ∑h∑ j| Ihj- 〈Ih〉|/∑h∑ j, where Ihj is the intensity of the jth observation of 
unique reflection h. 
bOverall R factor ∑h||Foh| - |Fch||/∑h|Foh| , where Foh and Fch are the observed and 
calculated structure factor amplitudes for reflection h. 
cFree R factor is equivalent to overall R factor , but is calculated using 5% of 
reflections excluded from the maximum-likelihood refinement stages. 
 
 
Data collection Crystal (data collected at in-house) 
Space group P21 
Unit cell parameters (Å) a = 41.10, b = 70.60, c = 51.38, β = 110.64 
Resolution (Å) 48.06 – 1.9 (1.97 – 1.9) 
Rmergea 0.033 (0.304) 
Observed reflections 135,957 
Unique reflections 21,026 
Completeness (%) 97 (96) 
< I / σ(I) > 62 (5.6) 
Multiplicity 6.5 (6.2) 
Refinement  
No. of protein atoms 2441 
No. of water atoms 194 
Resolution limits (Å)              48.06 – 1.9 
Number of used reflections            19,870 
R factorb                          0.227 
Free R factorc                            0.275 
RMSD bond lengths (Å) 0.010 
RMSD bond angles (°) 1.339 
Average B-factor (Å2) for protein 36.22  
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3.5.3 VC0509 crystal 
The crystals of VC0509 were cryoprotected and diffracted to 2.36 Å and the 
data were integrated and scaled by using the program HKL2000 (Otwinowski 
and Minor, 1997) and the CCP4 (CCP4., 1994) suite. The spacegroup of the 
crystal was H3. Two monomers were present per asymmetric unit of VC0508 
crystal which gave 56% solvent content and a Matthews coefficient of 
2.83 Å3/Da as revealed by the analysis of solvent contents in the crystal 
(Kantardjieff and Rupp, 2003; Matthews, 1968). To obtain phases for VC0509, 
a automated molecular replacement server BALBES (Long et al., 2008) was 
used. The search model was the VC1805 structure (PDB code 2v1l) which 
has 26% sequence identity to VC0509. The initial model had an R-factor of 
0.428 and an Rfree of 0.496. The partially built output model obtained from the 
server was built up manually using the program COOT (Emsley and Cowtan, 
2004) followed by refinement using REFMAC (Murshudov et al., 1997) and 
PHENIX (Adams et al., 2002). This process was repeated several times and 
the final R-factor and Rfree were 0.202 and 0.249, respectively.  The statistics 
of data collection and refinement for VC0509 are summarized in Table 3.3. 
Part of the final 2Fo-Fc electron density map is shown in Figure 3.14.  
 88 
Table 3.3 Data collection and refinement statistics of VC0509 crystal. 
Numbers in parentheses refer to highest resolution shell. 
 
aRmerge = ∑h∑ j| Ihj- 〈Ih〉|/∑h∑ j, where Ihj is the intensity of the jth observation of 
unique reflection h. 
bOverall R factor ∑h||Foh| - |Fch||/∑h|Foh| , where Foh and Fch are the observed and 
calculated structure factor amplitudes for reflection h. 
cFree R factor is equivalent to overall R factor , but is calculated using 5% of 
reflections excluded from the maximum-likelihood refinement stages. 
 
 
Data collection Crystal (data collected at in-house) 
Space group H3 
Unit cell parameters (Å) a = b = 153.77, c = 42.21 
Resolution (Å) 76.92 – 2.36 (2.44 – 2.36) 
Rmergea 0.048 (0.302) 
Observed reflections 42,268 
Unique reflections 15194 
Completeness (%) 99 (93) 
< I / σ(I) > 15.7 (2) 
Multiplicity 2.8 (2.4) 
Refinement  
No. of protein atoms 2520 
No. of water atoms 124 
Resolution limits (Å)              76.92 – 2.36 
Number of used reflections            14412 
R factorb                          0.218 
Free R factorc                            0.259 
RMSD bond lengths (Å) 0.010 
RMSD bond angles (°) 1.209 
Average B-factor (Å2) for protein 50.65  
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Figure 3.14 Stereo view of 2Fo-Fc electron density map of VC0509. A region 
of the map is shown, contoured at 1σ. 
3.6 Overall structure 
3.6.1 Structure of VC1805 
Using multiple heavy atom isomorphous replacement, the crystal structure of 
VC1805 was solved at a resolution of 2.13 Å. The crystals belong to the 
P3121 spacegroup and contain one molecule per asymmetric unit. The crystal 
structure of VC1805 reveals a flat seven-stranded anti-parallel β-sheet with 
two helices sitting on the same face of the sheet. The first helix (α1) is at the 
N-terminus, followed by six β-strands (β1 to β6) of varying length that form a 
simple consecutive up-down topology. The second helix (α2) then stretches 
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back across these six β-strands, leading to a seventh strand (β7) at the C-
terminus that completes the sheet. There are four disordered regions where 
no electron density was observed: the first four residues (1-4), the connection 
between α1 and β1 (31-39), the loop connecting β3 and β4 (84-86) and the 
final three residues (146-148). A cartoon representation based on 
crystallographic B-factor and surface topology of VC1805, is shown in 
Figure 3.15.A-B. The theoretical pI of the protein is 4.99 which is reflected by 
the negatively charged surface calculated by APBS (Baker et al., 2001) 
shown in Figure 3.15.C.The structure of VC1805 was validated by the 
Molprobity server which shows that the structure is in the top 37% for the 
corresponding resolution with a Molprobity score of 2.22 (64th percentile). In 
the Ramachandran plot 96.8% of the residues are present in the favored 
regions and the rotamer outliers are 2.7% (Davis et al., 2007). 
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3.15 Structure of VC1805 
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(A) Cartoon representation of the VC1805 structure which is colored by 
crystallographic B-factor (dark blue, B∼19 Å2 to red, B∼76 Å2). The black 
dotted lines are the disordered regions, N denotes N-terminus and C denotes 
C-terminus of the protein. (B) Surface topology of chain A of VC1805. There 
are a total of seven anti-parallel β-strands and two α-helices. (C) Electrostatic 
surface of VC1805 from -6 kT/e to +6 kT/e, calculated using APBS (Baker et 
al., 2001). 
3.6.2 Structure of VC0508 
The crystal structure of VC0508 was solved to a resolution of 1.9 Å using 
molecular replacement. The crystal belongs to the P21 spacegroup and 
contains two molecules per asymmetric unit. Residues 3-83 and 86-147 of 
monomer A, and residues 5-28 and 40-146 monomer B are well ordered. The 
RMSD (root mean square deviation) fit between chain A and B is 0.98 Å, 
revealed by SSM (Krissinel and Henrick, 2004) analysis. The buried surface 
area of VC0508 in the asymmetric unit is 720 Å2 with the complexation 
significance score (CSS) of 0.0 which was calculated by the PISA server 
(Krissinel and Henrick, 2007). The CSS score may depend on the interface 
area, residue/ atom composition and contacts, hydropathy index, charge 
distribution and topological complementarity (Krissinel and Henrick, 2007). 
The CSS score ranges from 0 to 1 as interface relevance to complexation 
increases. The results therefore indicate that the VC0508 interface might be 
an artifact of crystal packing. A cartoon representation of VC0508 (chain A) is 
shown in Figure 3.16.A, which is based on crystallographic B-factor. The 
structure of VC0508 has the same topology as VC1805. The surface topology 
and negatively charged surface of chain A of VC0508 is shown in 
Figure 3.16.B-C. Molecules in the asymmetric and unit cell of the crystal of 
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VC0508 is shown in Figure 3.17 and Figure 3.18, respectively. The final 
coordinates of the protein were analysed by the Molprobity server which 
shows that the structure is in the top 20% for the corresponding resolution 
with a Molprobity score of 1.55 (94th percentile). In the Ramachandran plot 
97.7% of the residues are present in the favored regions and the rotamer 
outliers are only 0.4% (Davis et al., 2007). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.16 Structure of VC0508 
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(A) Cartoon representation of the VC0508 structure (chain A) which is colored 
by crystallographic B-factor (dark blue, B∼23Å2 to red, B∼52Å2). The black 
dotted lines are the disordered region, N denotes N-terminus and C denotes 
C-terminus of the protein. (B) Surface topology of chain A of VC0508. A total 
of seven anti-parallel β-strands lie on top of two α-helices. (C) Electrostatic 
surface of chain A of VC0508 from -6 kT/e to +6 kT/e, calculated using APBS 
(Baker et al., 2001). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.17 Molecules in the asymmetric unit of VC0508 crystal 
(A) The crystallographic dimeric form of VC0508. Chain A is green in colour 
whereas chain B is cyan in colour. (B) Ribbon representation of VC0508 
dimer. 
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Figure 3.18 Molecules in the unit cell of VC0508 crystal. In the crystal, the 
protein is packed in such a way that β-strands of adjacent molecules form a 
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continuous β-sheet. This is likely to be an artifact of crystallization. (A) Stereo 
view of molecules in P21 unit cell of VC0508. Chain A is green in colour 
whereas chain B is cyan in colour (B) Stereo view of molecules in P21 unit cell 
of VC0508 with the surface of chain A and B in the asymmetric unit. 
3.6.2 Structure of VC0509 
The VC0509 crystal diffracted to a resolution of 2.36 Å, and the structure was 
solved by molecular replacement. The asymmetric unit of the VC0509 crystal 
contains two molecules of protein and the crystal belongs to the spacegroup 
H3. The last residue (Asn147) is missing in both chains A and B. The RMSD 
fit between chain A and B of VC0509 structure is 0.85 Å, revealed by SSM 
(Krissinel and Henrick, 2004) analysis. Analysis by the PISA server (Krissinel 
and Henrick, 2007) revealed that the buried surface area of VC0509 in the 
asymmetric unit, which contains two molecules, is 1012 Å2 with the CSS 
score of 0.1, indicating that the interface might be the result of crystal packing. 
The overall structure chain A of VC0509, coloured by crystallographic B-factor 
is shown in Figure 3.19.A. The N-terminus of the protein starts with the first 
helix (α1) followed by first anti-parallel β-sheet (β1), a small α-helix (α2), five 
consecutive anti-parallel β-sheets (β2 to β6) connected to the third helix (α3) 
and the seventh anti-parallel β-sheet (β7). The surface topology and 
negatively charged surface of chain A of VC0509 is shown in Figure 3.19.B-C. 
Molecules in the asymmetric and unit cell of the crystal of VC0508 are shown 
in Figure 3.20 and Figure 3.21, respectively. The overall structural quality was 
analyzed by the Molprobity server which shows the structure is in the top 13% 
for the corresponding resolution with a molprobity score of 1.6 (99th 
percentile). In the Ramachandran plot 98.7% of the residues are present in 
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the favored regions and the rotamer outliers are only 0.7% (Davis et al., 
2007). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.19 Structure of VC0509 
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(A) Cartoon representation of the VC0509 structure (chain A) which is colored 
by crystallographic B-factor (dark blue, B∼37 Å2 to red, B∼69 Å2). N denotes 
N-terminus and C denotes C-terminus of the protein. (B) Surface topology of 
chain A of VC0509. There are a total of seven anti-parallel β-strands and 
three α-helices. (C) Electrostatic surface of chain A of VC0509 from -6 kT/e to 
+6 kT/e, calculated using APBS (Baker et al., 2001). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.20 Molecules in the asymmetric unit of VC0509 crystal 
(A) The crystallographic dimeric form of VC0509. Chain A is blue in colour 
whereas chain B is cyan in colour. (B) Ribbon representation of VC0509 
dimer. 
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Figure 3.21 Molecules in the unit cell of VC0509 crystal. (A) Stereo view of 
molecules in H3 unit cell of VC0509. Chain A is blue in colour whereas chain 
B is cyan in colour (B) Stereo view of molecules in H3 unit cell of VC0509 with 
the surface of chain A and B in the asymmetric unit. 
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3.7 Multiple sequence alignments and conserved amino acids 
A sequence similarity search with BLAST (Altschul et al., 1997) and multiple 
sequence alignment with CLUSTAL-W (Chenna et al., 2003) indicated that 
VC0508 is a conserved hypothetical protein with high sequence identity 
among different Vibrio spp. as well as other pathogenic bacteria. The 
sequence identities of VC0509, VC1804, VC1805, V. cholerae non-O1, 
V. harveyi, V. splendidus, V. vulnificus, V. alginolyticus, V. fischeri, 
Providencia stuartii, Yersinia intermedia and Aeromonas hydrophila to 
VC0508 are 26, 20, 59, 99, 84, 81, 94, 50, 48, 38, 45 and 37%, respectively 
(Figure 3.22). All of the proteins listed in Figure 3.18 carry a negative charge 
having isoelectric points between 4.44 and 5.36. There are 9 amino acids that 
are invariant among this family and these are mapped onto the surface of 
VC0508 (chain A) and coloured blue in Figure 3.23.A. If we analyze the 
sequence identities among VC0509, VC1804, VC1805 and VC1805, then a 
total of 16 amino acids residues are conserved, indicated by the green arrows 
in Figure 3.22, which are also mapped onto the surface of VC0508 in red and 
shown in Figure 3.24.A. There appear to be two conserved patches, both 
carrying a negative potential, on opposite sides of the protein. One patch 
forms a groove formed between α2 and the loop connecting β1 and β2 with 
the invariant Tyr50 and His58 coming close in space at one end of the groove 
(Figure 3.23.B, left hand image). The other patch is centred around another 
groove on the opposite face that includes a deep hole lined with invariant 
residues Pro59, Glu61, Phe80 (Figure 3.23.B, right hand image). It is 
interesting to note that VC1804 would be predicted to be missing the first 
helix, a region that does not contain any conserved residues. Among the 
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conserved residues, Pro59, Gly56 and Gly109 might have a structural role as 
they interrupt the regularity of the α-helical backbone conformation. 
Hydrophobic residues Tyr50, Trp72, Leu94, Phe96, Leu122, Trp126 and 
Phe130 are buried in the hydrophobic core and are likely to be structurally 
important (Figure 3.24.B). Surface exposed conserved residues are Glu61, 
Val42 and Thr145. Being hydrophobic, surface exposed Val42 might be 
involved in binding and recognition of hydrophobic ligands (Figure 3.24.B). 
 
 
 
 
 
 
 
 
 
 
Figure 3.22 Multiple sequence alignment of VC0508 homologues. Green 
arrows indicate the conserved residues among VC0508, VC0509, VC1804 
and VC1805. The secondary structure of VC0508 is shown on the top line. 
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NCBI entry name and genome annotation name for the sequences are 
V. cholerae VC0508 (NP_230159, VC0508), V. cholerae VC0509 
(NP_230160, VC0509), V. cholerae VC1804 (NP_231439, VC1804), 
V. cholerae VC1805 (NP_231440, VC1805), V. cholerae non O1 
(ZP_01956054, A51_B0486), V. harveyi (ZP_01986167, AIQ_2013), 
V. splendidus (ZP_00989426, V12B01_02775), V. vulnificus (NP_933316, 
VV0523), V. cholerae VC1805 (NP_231440, VC1805), V. alginolyticus 
(ZP_01262456, V12G01_09492), V. fischeri (YP_206478, VF_A0520), 
Providencia stuartii (ZP_02961693, PROSTU_03744), Yersinia intermedia 
(ZP_00835059, YintA_01000511) and Aeromonas hydrophila (YP_855622, 
AHA_1080). Alignment was created by with CLUSTAL-W (Chenna et al., 
2003) and the figure was produced by ESPRIPT (Gouet et al., 1999). 
 
 
 
 
 
 
 
 
Figure 3.23 Location of the 9 conserved residues of VC0508. (A) Residues 
conserved across VC0508 homologues are mapped on the surface of 
VC0508 (chain A) and coloured in blue. (B) The positions of these conserved 
residues in the structure of VC0508 (chain A) are shown coloured in blue.  
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Figure 3.24 Location of the 16 conserved residues of VC0508 
(A) Residues that are conserved among VC0508, VC0509, VC1804 and 
VC1805 are mapped onto the surface of VC0508 (chain A) and coloured in 
red. (B) The positions of these conserved residues in the structure of VC0508 
(chain A). Hydrophobic conserved residues are coloured in blue and other 
conserved residues are coloured red. 
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Chapter 4 
Functional studies of VC0508, VC0509, and VC1805 and discussion  
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4. Functional studies of VC0508, VC0509, and VC1805 and discussion 
One of the proteins encoded by the 20 kb truncated version of VPI-2, named 
VC1805, is a hypothetical protein. Interestingly, a total of four proteins, 
VC0508, VC0509, VC1804 and VC1805 that are homologous/ paralogous to 
each other are present in two different pathogenicity islands, VSP-2 and VPI-
2. In this chapter, the structural comparisons of VC0508, VC0509, and 
VC1805 with one another and with their structural homologue p32 will be 
discussed. One of the binding partners of p32 is a plasma complement 
component C1q, which has been found to bind to VC1805. Single crossovers 
for the construction of VC0508/ VC0509 and VC1804/ VC1805 double 
knockouts have also been produced.  
4.1 Overall structural comparison 
The topology of VC0508, VC0509 and VC1805 is remarkably similar. 
Superposition of these structures is shown in Figure 4.1. Using SSM (Krissinel 
and Henrick, 2004) analysis, chain A of VC0508 shows an RMSD fit of 2.27 Å 
over 136 Cα atoms (sequence identity 18%) with chain A of VC0509 and 
RMSD fit of 1.33 Å over 129 Cα atoms (sequence identity 60%) with VC1805, 
respectively. Chain A of VC0509 shows an RMSD fit of 1.74 Å over 121 Cα 
atoms (sequence identity 26%) with VC1805. Sequence comparisons had 
failed to suggest a fold or function for VC0508, VC0509 and VC1805. The 
coordinates of VC0508, VC0509 and VC1805 were submitted to the ProFunc 
server (Laskowski et al., 2005), that revealed a structural homology with 
human p32 (PDB code 1p32) an acidic mitochondrial matrix protein. Human 
p32 is a homotrimer with each chain containing three helices and a seven-
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stranded anti-parallel β-sheets, and has a pI of 4 (Jiang et al., 1999). SSM 
(Krissinel and Henrick, 2004) analysis revealed that, respectively, chain A of 
VC0508, chain A of VC0509 and VC1805 have RMSD fits of 2.59 Å over 
72 Cα atoms (sequence identity 4%); 2.38 Å over 73 Cα atoms (sequence 
identity 8%) and 2.51 Å over 70 Cα atoms (sequence identity 4%) with chain 
A of human p32 protein, respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 Superposition of VC0508, VC0509 and VC1805 
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(A) Cartoon representation of VC0508 (green), VC0509 (blue) and VC1805 
(red). (B) Ribbon representation of VC0508 (green), VC0509 (blue) and 
VC1805 (magenta). 
4.2 Structural comparison of VC1805 and human p32  
The structures of VC0508, VC0509 and VC1805 show significant structural 
homology to human p32 protein but the sequence identities are only 11, 11 
and 6%, respectively. Although p32 has a low pI, the charge distribution is 
asymmetric with one face of the p32 trimer carrying a predominantly negative 
charge, and the other face far less negative (Figure 4.2). There is little 
sequence similarity between VC1805 and p32, and the residues forming the 
two patches conserved within the VC1805 family are not conserved in p32. 
Conversely, the two regions conserved among the eukaryotic homologues of 
p32 are not conserved in VC1805 (Jiang et al., 1999). The structural 
comparison of VC1805 and p32 reveals that the conserved fold between the 
two proteins involves the seven-stranded β-sheet and the helix (α2) that 
straddles the sheet, although the connectivity is slightly different (Figure 4.3). 
Human p32 has two long helices at its N- and C-termini that are involved in 
the association with other monomers in the p32 trimer. The first β-strand after 
the N-terminal helix of p32 is in the same location as β7 in VC1805, but from 
then on the topology is the same for both proteins until the structurally 
conserved helix (α2) which in p32 is slightly shorter and turns 90° to form the 
C-terminal helix that associates with the long N-terminal helix. As noted 
above, in VC1805 the final strand of the sheet (β7) follows helix α2. The only 
homologous structure to p32 in the protein databank is that of a hypothetical 
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protein LMAJ011689 from Leishmania major (PDB code 1yqf) that shares 
only 16% sequence identity with human p32 and 15% sequence identity with 
VC1805. Like p32, LMAJ011689 has a low pI of 4.5, and possesses the same 
trimeric structure with monomers having an RMSD fit of 1.64 Å over 155 Cα 
atoms using SSM (Krissinel and Henrick, 2004). The p32 fold is therefore an 
unusual fold in the current protein databank, so the fact that VC1805 shares 
the same core fold of a helix straddling a seven-stranded anti-parallel β-sheet, 
and also has a dominant negative charge potential, suggests that the proteins 
may have a related function.  
 
 
 
 
 
 
 
 
 
 
Figure 4.2 Structure of human mitochondrial protein p32 
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 (A) Cartoon representation of p32 protein which is coloured by chain where 
chain A is cyan, chain B is green and chain C is red. (B) Electrostatic surface 
of p32 protein from -26 kT/e to +26 kT/e, calculated using APBS (Baker et al., 
2001). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3 Superposition of VC1805 with human p32. (A) Cartoon 
representation of VC1805 (magenta) and chain A of human p32 protein 
(cyan). N denotes N-terminus and C denotes C-terminus of the protein. (B) 
Surface topology of chain A of p32. 
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4.3 Functional aspects 
4.3.1 C1q studies 
Human p32 protein, a structural homologue of VC0508, VC0509 and VC1805, 
is an evolutionarily conserved eukaryotic protein originally discovered in 
association with the nuclear pre-mRNA splicing factor SF2/ ASF, although no 
evidence for a splicing function has been reported (Krainer et al., 1991). 
Human p32 is a promiscuous protein, reported to bind to many viral proteins 
(Bruni and Roizman, 1996; Desai et al., 1991; Matthews and Russell, 1998; 
Tange et al., 1996; Wang et al., 1997; Yu et al., 1995), transcription factor IIB 
(Yu et al., 1995), the lamin B receptor (Simos and Georgatos, 1994), high 
molecular weight kininogen and factor XII (Herwald et al., 1996), vitronectin 
(Lim et al., 1996), hyaluronic acid (Deb and Datta, 1996) and the globular 
head domain of the plasma complement component C1q (Ghebrehiwet et al., 
1994).  
We were interested to explore the functional aspects of VC1805 with C1q as a 
quest to reveal any functional clues for this hypothetical protein family. C1q 
was found to bind to VC1805 immobilized on microtitre plate wells 
(Section 2.21 and Figure 4.4.A). Immobilized VC1805 also caused 
complement consumption when incubated with human serum (Section 2.22 
and Figure 4.4.B), indicating that VC1805 binds C1 and activates the 
complement classical pathway. Complement consumption by VC1805 was at 
a similar level (25–30%) to consumption by immune complexes. C1, a 
complex of C1q with the serine protease proenzymes C1r and C1s, is the 
form in which C1q circulates in blood (Figure 4.4.B).  
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Figure 4.4 Binding of VC1805 to C1q. (A) ELISA assay showing C1q binding 
VC1805 with negative controls. (B) Complement consumption assay. Error 
bars, calculated using triplicate results, are included in the graph but are too 
small to visualize. The non-coated control plate gives 50% lysis with 13.2% 
serum at a 1/10 dilution (indicated by green arrow). The 1/10 diluted serum 
has 100/13.2 = 7.58 units per 100 µL, which corresponds to 758 units per mL 
of undiluted serum. VC1805 and ovalbumin anti-ovalbumin coated plate give 
50% lysis with 17.5% serum at a 1/10 dilution (indicated by green arrow). The 
1/10 diluted serum has 100/17.5 = 5.71 units per 100 µL which corresponds to 
571 units per mL of undiluted serum. A and B have 75.33% of the activity of C 
which reflects 24.67% complement consumption by both A and B.  
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There was also no consistent dose-dependent complement inhibitory effect 
when soluble VC1805 was added to serum. This is consistent with the 
requirement for multivalent binding of C1q to a target array to initiate 
complement activation. Thus soluble VC1805, which is a monomer in solution, 
may bind weakly to sites on the C1q globular heads, but engagement of two 
or more heads of C1q, and summation of multiple weak interactions, as can 
occur with an array of immobilized VC1805, is required for high avidity C1q 
binding and complement activation. 
4.4 Gene knockout  
4.4.1 Overview 
To find out the exact role of VC0508, VC0509, VC1804 and VC1805 proteins 
in V. cholerae pathogenesis, knockouts of those genes were made by SOE-
PCR. The ultimate target was to test knockout stains of V. cholerae in an 
animal model to find out whether there are any significant differences in 
pathogenesis compared to wild type strain. A series of experiments was 
designed to produce three different mutant strains which are termed M050809 
(double mutant of VC0508 and VC0509 of V. cholerae N16961), M180405 
(double mutant of VC1804 and VC1805 of Vibrio cholerae N16961) and 
M04050809 (quadruple  mutant of VC0508, VC0509, VC1804 and VC1805 of 
V. cholerae N16961).  
4.4.2 Cloning SOE-PCR  products in pCR 2.1 –TOPO vector 
A total of six primers for each construct were designed (Table 2.3) which 
contained a portion of the beginning and the end of the mutant gene of 
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interest (M050809 and M180405). The genes were successfully amplified and 
ligated using the procedures described earlier (section 2.23.3-4 and 
Figure 4.5.A-B). The ABCD products (Figure 2.5) of M050809 and M180405 
were cloned into pCR 2.1 –TOPO and the positive clones were confirmed by 
blue/white screening and colony PCR (Figure 4.5.C-D). 
 
 
 
 
 
 
 
 
Figure 4.5 Cloning SOE-PCR  products in pCR 2.1 –TOPO vector 
(A) SOE-PCR of target genes. M, 100 bp DNA ladder (NEB, USA); lane 1, AB 
products of M050809 (278 bp); lane 2, CD products of M050809 (301 bp); 
lane 3, AB products of M180405 (270 bp); lane 4, CD products of M180405 
(295 bp). (B) PCR reaction to ligate beginning and end of gene. M, 1 kb DNA 
ladder (NEB, USA); lane 1, ABCD products of M050809 (579 bp); lane 2, 
ABCD products of M180405 (565 bp). (C) Transformed colonies on LB-Amp 
plate. Blue colonies are galactose fermentor whereas white colonies are non-
galactose fermentor and are possibly the right constructs. (D) Colony PCR to 
screen for the correct insert in pCR2.1-TOPO vector. M, 1 kb DNA ladder 
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(NEB, USA); lane 1, correct insert of M050809 of 579 bp; lane 2, correct insert 
of M180405 of 565 bp. 
4.4.3 Single crossover mutants 
ABCD products of M050809 and M180405 in pCR 2.1–TOPO, were 
successfully cloned into pADS132 plasmid using the procedure described 
earlier (section 2.23.6). The recombinant plasmids were then purified and 
transformed into V. cholerae O1 El Tor (section 2.23.7). The aim of single 
crossover was selection of plasmid integration into the recipient chromosome 
(which does not carry the pir gene) through allelic exchange by plating cells 
on chloramphenicol-LB plates. As V. cholerae O1 El Tor is not resistant to 
chloramphenicol, the observed growth of the strains in chloramphenicol-LB 
plate indicates the presence of recombinant pADS132 plasmid on the 
chromosome of the strain. This event is likely to produce single cross-over 
recombination due to the presence of a small piece of homologous DNA to 
V. cholerae O1 El Tor in pADS132 plasmid. The positive single crossover was 
validated by colony PCR using internal (AD) and flanking primers (EF) 
(Table 2.3). For positive single crossover, an internal primer should give a 
product smaller (ABCD products, Figure 2.5) than wild type, whereas the 
flanking primer would not give any product, as the whole plasmid of pADS132 
sits in an amplification region which needs a higher extension time (about 
6 min) in PCR. The absence of flanking products and the presence of internal 
products confirmed the construction of single crossover mutant (Figure 4.6). 
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Figure 4.6 Construction of single crossover mutants 
(A) Double digest of pCR2.1-TOPO vector containing insert gene of interest 
and pADS132. M, 1 kp DNA ladder (NEB, USA); lane 1 (upper band) digested 
pTOPO of M050809 construct of 3.85 kb; lane 1 (lower band), digested 
M050809 inserts of 0.66 kb (ABCD products with restriction site); lane 2 
(upper band), digested pTOPO of M180405 construct of 3.85 kb; lane 2 (lower 
band), digested M180405 inserts of 0.64 kb (ABCD products with restriction 
site); lane 3, digested linerized pADS132 suicide vector of 5.2 kb. (B) Colony 
PCR to screen colonies contain M050809 insert with vector pADS132. Lane 
1-2, ABCD products of M050809 of 579 bp. (C) Colony PCR to screen 
colonies contain M180405 insert with vector pADS132. Lane 1-2, ABCD 
products of M180405 of 565 bp. (D) Single crossover in V. cholerae by 
pADS132 containing homologous region of M050809. Lane 1 and 3, Internal 
product of M050809, AD (579 bp); lane 2 and 4, No flanking products of 
M050809, EF (1.9 kb); lane 5, positive control of 1.9 kb flanking products of 
wild type V. cholerae. (E) Single crossover in V. cholerae by pADS132 
containing homologous region of M180405. Lane 1 and 3, Internal product of 
M180405, AD (565 bp); lane 2 and 4, No flanking products of M180405, EF 
(1.8 kb); lane 5, positive control of 1.8 kb flanking products of wild type 
V. cholerae. 
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4.4.4 Double crossover mutants 
The growth of single crossover mutants V. cholerae O1 El Tor in the presence 
of sucrose will assist the removal of the pADS132 plasmid from its 
chromosome. The plasmid pADS132 contains the sacB gene which encodes 
the secreted enzyme levansucrase. This enzyme catalyzes the hydrolysis of 
sucrose and the synthesis of levans (high-molecular-weight fructose 
polymers) which are lethal for Gram-negative bacteria (Gay et al., 1985; 
Rapoport and Dedonder, 1966). During excision of plasmid from host 
chromosome, some of the plasmid will participate in homologous 
recombination with the host chromosome (V. cholerae O1 El Tor) due to the 
presence of host chromosome specific homologous regions in the pADS132 
plasmid. Excision of plasmid was confirmed from both mutants of M050809 
and M180405, as there was no growth in LB plates containing 
chloramphenicol but there was growth in sucrose containing plates 
(Figure 4.7). Screening of double crossover mutants and animal model 
studies are underway. 
 
 
 
 
Figure 4.7 Double crossover mutant screening by sucrose sensitivity plating 
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(A) LB plate with 10% sucrose and Streptomycin at 10-7 dilution of M050809 
mutant. (B) Colonies of M050809 mutant on LB 10% sucrose. (C) No colonies 
of M050809 mutant on chloramphenicol containing LB plate. 
4.5 Discussion  
Genome sequencing of microorganisms started a new era for scientists 
working in different areas of life sciences. More than 420 bacterial genomes 
have been sequenced to date (February 2009) (http://cmr.jcvi.org/tigr-
scripts/CMR/shared/Genomes.cgi). In a newly sequenced genome, 30 to 40% 
of genes are annotated having no function (Bork, 2000), or named as 
hypothetical protein if the gene is unique to the genome, or named as 
conserved hypothetical proteins if the gene is found in more than one genome 
(Roberts, 2004). The complete understanding of a microbial organism 
requires the proper understanding of its non-annotated genes. Determination 
of the three-dimensional structure of a protein is very important in 
understanding its function at the atomic level, but achieving this goal is often 
difficult and expensive. Generally, determination of a structure would cost 
about $66,000 in the present day, but back in 2002 it was four times more 
costly (Lattman, 2004; Service, 2008). Structural genomics consortia around 
the world are putting a great deal of effort and money into solving the three-
dimensional structures of novel proteins including hypothetical or conserved 
hypothetical proteins which often provide excellent clues about the function of 
hypothetical proteins (Zarembinski et al., 1998). 
Genes which sit on pathogenicity islands are of great interest as they are 
likely related to the pathogenesis of the organism. In a quest to find out the 
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role of hypothetical genes in the pathogenicity island, I designed some 
experiments to investigate structural, biochemical and microbiological analysis 
of four hypothetical proteins present in VPI-2 and VSP-2 of V. cholerae El Tor 
O1 pathogenic strain. These proteins, VC0508, VC0509, VC1804 and 
VC1805, are homologues and paralogues to each other, and share the same 
folds as revealed by PSI-BLAST (Altschul and Koonin, 1998) and PHYRE 
(Bennett-Lovsey et al., 2008). I have cloned all four genes of vc0508, vc0509, 
vc1804 and vc1805 as part of the structural investigation. Proteins expressed 
from these genes were soluble with the exception of VC1804 even after 
extensive optimization. About 40 amino acid residues at the N-terminal of the 
protein are missing in VC1804 (104 aa) compared to VC0508 (147 aa), 
VC0509 (147 aa) and VC1805 (148 aa) which could be essential for the 
solubility of this protein. 
VC0508, VC0509, VC1804 and VC1805 all carry a predominantly negative 
charge. The presence of those proteins in all pathogenic strains of 
V. cholerae, and other pathogenic strains, suggests that these proteins must 
have a role that gives an advantage to those strains of V. cholerae 
possessing them. There are a number of other Vibrio spp. and γ-
proteobacteria that have homologues to those proteins: V. harveyi which is a 
pathogen of fish and invertebrates, including sharks, seahorses, lobster and 
shrimp; V. splendidus is associated with mortality in a variety of marine 
animals including fish, oysters, mussels, and scallops; V. vulnificus may 
cause gastroenteritis and can enter into the blood stream, resulting in septic 
shock with a mortality rate of about 50%; V. alginolyticus is an opportunistic 
pathogen that may cause disease in marine cultured animals, including fish, 
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shellfish and shrimp; P. stuartii is also an opportunistic pathogen which may 
cause invasive diarrhea; Y. intermedia may cause enterocolitis in humans; 
A. hydrophila may cause cholera like gastroenteritis and dysenteric 
gastroenteritis in humans and may cause disease in fish and amphibians. So 
the complete understanding of the functional aspects of this protein could 
answer some questions regarding pathogenicity in different organisms. 
The crystal structures VC0508, VC0509 and VC1805 have been solved to 
1.9  Å, 2.4 Å and 2.1 Å resolution, respectively. The structures of these 
proteins reveal the same folds, in agreement with the prediction made by 
sequence analysis. The structures of VC0508, VC0509 and VC1805 have an 
unusual topology which includes a flat seven-stranded, anti-parallel β-sheet 
and α-helices and shows structural homology to human p32 protein. Of the 
many reported binding partners of p32, the binding to the globular head 
domain of the complement component C1q appeared worthy of exploration. In 
our experiment, we found that VC1805 does bind to the complement protein 
C1q. In fact, C1q can bind a remarkable variety of immune and non-immune 
ligands through charge pattern recognition mediated mainly through its 
globular head domain (Ghai et al., 2007). The crystal structure of the globular 
head domain of human C1q revealed the heterotrimeric organization of the 
three chains each with similar jelly-roll topology (Gaboriaud et al., 2003). The 
three modules within the C1q head domain show clear differences in their 
electrostatic surface potentials, with one module carrying a predominantly 
positive charge that has been implicated in the C1q-IgG interaction 
(Gaboriaud et al., 2003). However, the details of the interactions between C1q 
and its various ligands remain to be elucidated (Malhotra et al., 1993).  
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V. cholerae is generally accepted to be a non-invasive gut pathogen, and is 
thought to be relatively non-inflammatory (Satchell, 2003; Silva et al., 1996), 
although a more recent report described an inflammatory response in both O1 
and O139 cholera infections (Qadri et al., 2004). Could VC1805 therefore be 
engaging C1q as part of a strategy to modify complement attack, or to 
mediate cell adhesion?  It would not be advantageous for V. cholerae to have 
a protein that would activate complement, but this would be consistent with 
V. cholerae being non-invasive. It is not known if VC1805 is secreted, and if 
so whether it remains attached to the bacterial surface. What therefore could 
be the relevance of binding to C1q? It is known that some other complement-
related components (DAF-CD55 and MCP-CD46) serve as anchors for gut 
microbes, but DAF and MCP are cell-surface proteins, not soluble like C1q.  
C1q is synthesized in gut epithelial cells (Loos et al., 1989; Morris et al., 1978) 
and may be present in the gut lumen, although this has been shown only in 
inflammatory bowel disease (Halstensen et al., 1992). C1q can associate with 
membranes via C1q receptors which bind the collagenous region of C1q. The 
identification of C1q receptors has been controversial, but it is now widely 
accepted that calreticulin, bound to cell surfaces via CD91, HLA class 1 heavy 
chain, or CD59, acts as a receptor for C1q and the related “defence 
collagens” SPA, SPD and MBL (Ghiran et al., 2003; Ogden et al., 2001; Sim 
et al., 1998). C1q receptor activity is present on lung epithelial cells (Malhotra 
et al., 1993), but it does not appear to have been investigated in gut 
epithelium.  
It may be fortuitous that VC1805, being negatively charged, happens to be 
able to bind to positively charged C1q in vitro, and this may be completely 
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unrelated to its biological function in vivo. Perhaps a role for VC1805 is to aid 
in cell adhesion and to act as a bridge between membrane immobilized C1q 
and some ligand on the bacterial surface and this may be consistent with the 
two conserved surface patches on opposite sides of VC1805.  
Human p32 also binds to hyaluronic acid, a non-sulfated glycosaminoglycan 
found in the extracellular matrix of epithelial tissues. Perhaps hyaluronic acid 
is the ligand recognized by VC1805. An intriguing scientific question is why 
V. cholerae keeps four copies of structurally similar proteins in its genome. 
The true biological role of these proteins remains to be discovered.  
4.6 Ongoing and future work 
This structural study of VC0508, VC0509 and VC1805 has stimulated further 
investigations that will focus on quantifying the interaction with C1q and 
carrying out pull-down experiments to identify other binding partner(s) in 
V. cholerae. To better understand the interactions of the VC0508, VC0509, 
VC1804 and VC1805 proteins with both human proteins and other V. cholerae 
pathogenicity island proteins, Y2H (yeast-two-hybrid) analyses are underway. 
These proteins are already cloned in prey vector pGADT7 and bait vector 
pGBKT7 in preparation for further Y2H experiments in the department of 
Systems Biology of Infectious Disease at the University of Edinburgh. In order 
to explore the potential role of VC0508, VC0509, VC1804 and VC1805 
in vivo, gene knockouts and animal model are currently underway. 
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5. Structural determination of Vibrio cholerae ferric uptake regulator 
This chapter describes the results of cloning, expression, purification and 
structural determination of V. cholerae ferric uptake regulator (VcFur). The 
structure VcFur was determined to 2.6 Å resolution, and revealed a dimeric 
molecule with each monomer containing a dimerization domain, a helical 
DNA-binding domain and two metal binding sites occupied by zinc. Like Fur 
from Pseudomonas aeruginosa (PaFur), VcFur has two metal binding sites. 
However, the Zn2 site which is proposed to be a structural Zn-binding site in 
PaFur, has different ligands in VcFur. 
5.1 Overview of Vibrio cholerae ferric uptake regulator (VcFur) 
The Vibrio cholerae ferric uptake regulator (VcFur) is a metalloprotein which is 
relatively small in size (about 17000 Da) (Litwin et al., 1992). Fur is a classical 
repressor protein and its main function is iron homeostasis but it can also 
regulate the genes involve in pathogenesis. A wide variety of Fur homologues 
are present widely in Gram-positive and Gram-negative human pathogens. 
The locus vc2106, containing the fur gene, encodes a protein of 150 amino 
acid residues and a calculated isoelectric point (pI) of 5.81. It has two 
domains involved in DNA binding and dimerization. In vitro, a number of other 
divalent cations can also activate Fur to bind DNA (Bagg and Neilands, 1987; 
de Lorenzo et al., 1987), and their binding affinities for Fur have been studied 
in detail: in the case of E. coil Fur (EcFur), Fe(II), Fe(III), Co(II), Mn(II) and 
Zn(II) all activate Fur binding to DNA (Mills and Marletta, 2005).  
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5.2 Multiple sequence similarity and conserved amino acids 
A sequence similarity search with BLAST (Altschul et al., 1997) and a multiple 
sequence alignment with CLUSTAL-W (Chenna et al., 2003) indicated that 
VcFur is a conserved member of the Fur family. There is a high sequence 
identity of VcFur homologues in different Vibrio sp. The sequence identities of 
Vibrio mimicus, Vibrio harveyi, Vibrio alginolyticus, Vibrio parahaemolyticus, 
Vibrio vulnificus, Vibrio splendidus and Vibrio fischeri to VcFur are 98, 96, 94, 
92, 93, 90 and 86% respectively. Among other pathogenic species such as 
Aeromonas hydrophila, Escherichia coli, Salmonella typhimurium, 
Yersinia enterocolitica, Klebsiella pneumoniae, Shewanella baltica, 
Yersinia pestis, Haemophilus influenzae, Legionella pneumophila, 
Pseudomonas aeruginosa, Neisseria gonorrhoeae, Bordetella pertussis and 
Neisseria meningitidis the sequence identities to VcFur are 82, 76, 77, 76, 76, 
78, 73, 58, 59, 58, 52, 53 and 52%, respectively. A multiple sequence 
alignment of VcFur homologues is shown in Figure 5.1. Metal binding 
residues of VcFur; His33, Glu81, His87, His88 Asp89, His90, Glu108 and 
His125, are conserved in all homologues and shown by green arrows in 
Figure 5.1. Using RONN analysis (Yang et al., 2005), it was found that 
residues 1, 72-86, and 141-150 in VcFur are predicted to be disordered 
(Figure 5.2). Interestingly, Cys139 is conserved in almost all the Fur 
homologues compared in Figure 5.1, except for P. aeruginosa. The aromatic 
amino acids (tryptophan, tyrosine and phenylalanine) tend to be more ordered 
in proteins (Kissinger et al., 1995). Cysteine and histidine are less common in 
disordered regions whereas charged residues like glutamate, aspartate and 
lysine are more likely to appear in disordered regions (Yang et al., 2005). 
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Figure 5.1 Multiple sequence alignment of VcFur homologues. The 
secondary structure of VC-Fur is shown on the top line. NCBI entry name and 
genome annotation name for the sequences are Vibrio cholerae N16961 Fur 
(NP_231738, VC2106) Vibrio mimicus (BAD24855, AB182655.1), 
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Vibrio harveyi (ABM89108, EF197913.1), Vibrio alginolyticus (ZP_01260898, 
V12G01_15725), Vibrio parahaemolyticus (NP_797212, VP0833), 
Vibrio vulnificus (NP_759186, VV1_0175), Vibrio splendidus (ZP_00992248, 
V12B01_21344), Vibrio fischeri (YP_204193, VF_0810), 
Aeromonas hydrophila (AAK28627, AF349468.1), Escherichia coli 
(NP_286398, Z0831) Salmonella typhimurium (NP_459678, STM0693), 
Yersinia enterocolitica (YP_001007162, YE2973), Klebsiella pneumoniae 
(YP_001334379, KPN_00706), Shewanella baltica (YP_001050871, 
Sbal_2509), Yersinia pestis (NP_406158, YPO2634), Haemophilus influenzae 
(ZP_00154690, Hflu103001406), Legionella pneumophila (YP_125780, 
lpl0414), Pseudomonas aeruginosa (NP_253452, PA4764), 
Neisseria gonorrhoeae (YP_002003120, NGK_2495), Bordetella pertussis 
(NP_881134, BP2507) and Neisseria meningitidis (YP_974323, NMC0197). 
Alignment was created by with CLUSTAL-W (Chenna et al., 2003) and the 
figure was produced by ESPRIPT (Gouet et al., 1999). 
 
 
 
 
 
 
 
 
Figure 5.2 RONN analysis of VcFur 
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5.3 Cloning of vc2106 gene 
The fur gene at locus vc2106 in the V. cholerae genome was successfully 
amplified using the polymerase chain reaction (PCR) from genomic DNA of 
V. cholerae O1 El Tor strain N16961 using standard protocols (Figure 5.3.A) 
(Section 2.4). Two primers commercially synthesized and purchased from 
VHBIO, forward (5′- CAGGAAAGTCCATGGCAGACAATAAC-3′) and reverse 
(5′- CGTAAAGAATTCGGTTATTTCTTCGGC-3′) were designed 
corresponding to the 5′ and complementary 3′ ends of fur gene with specific 
recognition sites for the restriction enzymes NcoI and EcoRI. The primers 
produce one mutation at position 2 of the protein from a serine to an alanine. 
After amplification, the PCR product was digested with NcoI and EcoRI 
enzymes and ligated with the similarly digested pEHISTEV vector 
(Section 2.6-7) (Liu and Naismith, 2009). Positive clones were verified by 
double digestion (Section 2.10.2) (Figure 5.3.B), and DNA sequencing at the 
University of Dundee (Section 2.10.3). 
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Figure 5.3 Agarose gel electrophoresis of vc2106 gene products 
(A) Amplification of vc2106 gene from genomic DNA of V. cholerae El Tor O1. 
M, 1 kb DNA ladder (Promega); lane 1, amplification of vc2106 gene product. 
(B) Colony PCR of cloning vector pLou3 contains vc2106 gene. Lane 1, 
colony PCR product of pEHISTEV vector containing vc2106 gene (indicated 
by red asterisk). 
5.4 Protein expression, optimization of solubility and purification  
The expression vector pEHISTEV containing the vc2106 gene was 
transformed in E. coli BL21 (DE3) using standard methods. The expression, 
optimization of solubility and purification was done according to the procedure 
described earlier (Figure 5.4.A-E) (Section 2.13). The best soluble protein 
expression was achieved after 24 h growth at 25 °C with the addition of 
0.5 mM IPTG. For crystallization trials, purified VcFur was pooled and 
dialysed overnight at 4 °C against 4 L of buffer containing 50 mM HEPES, 
500 mM NaCl, 10 mM imidazole and 10% (v/v) glycerol, 5 mM DTT and 1 mM 
ZnCl2. Next day, the sample was dialysed against the same buffer without 
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DTT and ZnCl2 for 4 h at 4 °C with two buffer changes. Finally, the protein was 
dialysed in 10 mM HEPES, 50 mM NaCl, 5% (v/v) glycerol. Mass 
spectrometry was carried out to confirm the identity of VcFur (Figure 5.4.F). 
 
 
 
 
 
 
 
 
 
Figure 5.4 Expression and purification of VcFur (VC2106) protein 
(A) First Ni2+-affinity column. M, protein marker (Mark12™, Invitrogen); lane 1, 
cell lysate after IPTG induction; lane 2, supernatant after sonication; lane 3, 
flow-through (unbound protein) after loading sample on to the column; lane 4-
6, column wash with the buffer containing 10 mM imidazole; lane 7-9, elution 
in buffer containing 350 mM imidazole. Bands indicated by the red asterisks 
are His-tagged VC2106. (B) TEV cleavage of his-tagged VC106. Lane 1, 
dialysed eluted protein from first Ni2+-affinity column; lane 2, TEV digested 
sample of VC2106. (C) Second Ni2+-affinity column. Lane 1, filtered TEV 
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digested sample; lane 2, VC106 without His-tag (D) Eluted VC2106 after gel 
filtration chromatography. Lane 1-3, fractions containing VC2106 protein. (E) 
Gel filtration peak corresponding to purified VC2106. (F) Matched peptides of 
VC2106 identified by mass spectrometry. 
5.5 Crystallization, optimization and X-ray data collection of VcFur 
The initial concentration of VcFur for crystallization was 7 mg/mL, as 
determined by the PCT. A total of six crystal screens were set up with three 
different concentrations which were 14 mg/mL, 10 mg/mL and 7 mg/mL. The 
screens were: The PEGs, Ammonium salt, pH clear, JCSG+, Classics 
(Qiagen) and Wizard I and II (Emerald Biosciences). Crystal plates were 
initially set up using the crystallization robot (Hamilton-Thermo Rhombix 
system), with 150 nl of buffer and 150 nl of protein per drop. After 4 weeks, 
initial hits with tiny rod shaped crystals were observed in two conditions of 
PEGs screen containing protein of 10 mg/mL (well number 55; 0.2 M calcium 
chloride dihydrate and 20% w/v PEG 3350; and well number 64; 0.2 M 
magnesium nitrate, and 20% w/v PEG 3350) (Figure 5.5.A-B). Crystal plates 
were set up at 10 mg/mL with a 192-condition optimization screen based on 
the initial hits. After 6 weeks, crystals suitable for X-ray analysis were 
produced in the condition 0.18 M magnesium nitrate and 16 % PEG 3350 
(Figure 5.5.C). Crystals were cryoprotected in crystallization buffer with the 
addition of 20% (v/v) glycerol, and X-ray data to 2.6 Å were collected at 100K 
on an in-house X-ray facility, a Rigaku/MSC MicroMax-007HF rotating anode 
equipped with focusing optics and a Saturn 944+ CCD detector 
(Figure 5.5.D). 
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Figure 5.5 VcFur protein crystal and diffraction pattern 
(A) Initial hits in PEGs screen (well number 55; 0.2 M calcium chloride 
dihydrate; 20% w/v PEG 3350). (B) Initial hits in PEGs screen (well number 
64; 0.2 M magnesium nitrate, and 20% w/v PEG 3350). (C) Optimized crystal 
in 0.18 M magnesium nitrate and 16 % PEG 3350. (D) X-ray diffraction image 
of VcFur protein crystal. The resolution of the outer circle is 2.4 Å. 
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5.6 Structure solution and refinement of VcFur 
X-ray data were integrated and scaled using HKL2000 (Otwinowski and 
Minor, 1997) and the CCP4 (CCP4., 1994) suite. The crystals belonged to the 
space group P41/3212. The unit cell suggested two monomers in the 
asymmetric unit giving a Matthews coefficient of 2.47 Å3/Da with a 50% 
solvent content. The structure of VcFur was solved by molecular replacement 
using the program PHASER (McCoy et al., 2007), by splitting the search 
model into two domains: the dimerization domain from PaFur (residues 84-
134 from PDB code 1MZB), and the DNA-binding domain made up by 
superimposing the DNA-binding domains from EcFur (PDB code 2FU4) and 
PaFur (residues 1-83 from PDB code  1MZB). Zinc atoms were removed from 
the search models. A solution with Z-scores of 6.3 and 29.2 for the rotation 
and translation function steps, respectively, was obtained in the space group 
P43212. The final model was built manually using the program COOT (Emsley 
and Cowtan, 2004) and the refinement was carried out using 
REFMAC(Murshudov et al., 1997) and PHENIX (Adams et al., 2002). The 
data collection and refinement statistics are summarized in Table 5.1. Atomic 
coordinates and structure factors have been deposited in the PDB (2w57). 
Part of the final 2Fo-Fc electron density map is shown in Figure 5.6.  
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Table 5.1 Data collection and refinement statistics of VcFur crystal. Numbers 
in parentheses refer to highest resolution shell. 
Data collection Crystal 
Space group P43212 
Unit cell parameters (Å) a = b = 88.88, c = 85.07 
Resolution (Å) 62.9 - 2.6 (2.74 – 2.6) 
Rmergea 0.128 (0.588) 
Observed reflections 94,782 
Unique reflections 10,961 
Completeness (%) 100 (100) 
< I / σ(I) > 16.6 (3.3) 
Multiplicity 8.6 (8.6) 
RFZ (rotation function Z-score) 6.3 
TFZ  (translation function Z-score) 29.2 
Refinement  
No. of protein atoms 2114 
No. of water atoms 80 
Resolution limits (Å)              62.9 - 2.60 
Number of used reflections            10,383  
R factorb                          0.207 
Free R factorc                            0.259 
RMSD bond lengths (Å) 0.007 
RMSD bond angles (°) 1.152 
Average B-factor (Å2) for chain A/B 
All protein atoms 
DNA-binding domain (3-82) 
Dimerization domain (83-133) 
Zinc atoms Zn1, Zn2  
Waters 
 
31 / 29 
26 / 27 
39 / 32 
 41,43 / 28,32  
 34 
 
aRmerge = ∑h∑ j| Ihj- 〈Ih〉|/∑h∑ j, where Ihj is the intensity of the jth observation of 
unique reflection h. 
bOverall R factor ∑h||Foh| - |Fch||/∑h|Foh| , where Foh and Fch are the observed and 
calculated structure factor amplitudes for reflection h. 
cFree R factor is equivalent to overall R factor , but is calculated using 5% of 
reflections excluded from the maximum-likelihood refinement stages. 
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Figure 5.6 Stereo view of 2Fo-Fc electron density map of VcFur. A region of 
the map is shown, contoured at 1σ. This and other figures were created with 
PyMOL (DeLano, 2007). 
5.7 Structure of VcFur  
The structure of VcFur reveals a dimer in the asymmetric unit. In each chain 
of the dimer, the first two amino acids and the last 17 amino acids (134-150) 
are not visible in the electron density map which is consistent with the RONN 
analysis (Figure 5.2). Each chain has two domains: the DNA-binding domain 
(residues 3-82) and the dimerization domain (residues 83-133), the latter of 
which has a disulfide bond connecting Cys93-Cys133 (Figure 5.7). The 
dimerization interface of VcFur has a buried surface area of ∼1350Å2, similar 
to the 1300 Å2 reported for the same interface in PaFur (Pohl et al., 2003). 
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Superposition of the two VcFur chains gives an RMSD of 1.33 Å for 130 Cα 
atoms, however separate superposition of the DNA-binding and dimerization 
domains gives RMSDs based on Cα atoms of 0.48 Å and 0.99 Å, 
respectively, reflecting a slightly different orientation of the DNA-binding 
domains in each subunit relative to the dimerization domain. The 
crystallographic B-factor distribution throughout the dimer shows that the 
DNA-binding domain is relatively well-ordered compared to the dimerization 
domain, and this is reflected in the higher RMSD between the two 
dimerization domains. The electrostatic charge distribution over the dimer is 
shown in Figure 5.8.A-B, and reveals a largely negatively-charged surface 
apart from the helical regions involved in DNA recognition, particularly helix 4 
(Figure 5.8.C). Two metal ions, refined as zincs, are present in each chain 
and have the same coordination in each chain. The electron density around 
each zinc in chain B is shown in Figure 5.9-10. The zinc in the dimerization 
domain, Zn1, is tetracoordinated by the following side chains where the 
distances refer to those observed in (chainA/ chainB): His87 (2.3/ 2.1 Å), 
Asp89 (2.0/ 1.9 Å), Glu108 (2.1/ 2.1 Å) and His125 (2.2/ 2.2 Å) (Figure 5.9 
and Table 5.2), these are the equivalent ligands to those in PaFur. The zinc 
that connects the DNA-binding and dimerisation domains, Zn2, is 
tetracoordinated by His33 (2.1/ 2.0 Å), Glu81 (2.1/ 2.1 Å), His88 (2.1/ 2.1 Å) 
and His90 (2.4/ 2.2 Å) (Figure 5.10 and Table 5.3). The significant difference 
in comparison to PaFur, is that His88 replaces Glu100 (in PaFur) as a ligand 
to Zn2 which is discussed below. 
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Figure 5.7 The structure of VcFur dimer 
(A) Schematic view of the secondary structure and location of the four zinc 
atoms, coloured by crystallographic B-factor (dark blue, B∼20Å2 to red, 
B∼50Å2). Black arrows indicate disulphide bonds. (B) 90° rotation of Figure 
5.5.A.  
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Figure 5.8 Electrostatic surface of VcFur 
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(A) Electrostatic surface of VcFur from -10 kT/e to +10 kT/e, calculated using 
APBS (Baker et al., 2001). (B) 90° rotation of Figure 5.6.A. (C) Orientation of 
helix-4 on the surface. 
 
 
 
 
 
 
 
 
Figure 5.9 Metal binding ligands at Zn1 site of VcFur. Stereo view of the 
electron density around the zinc atoms in the Zn1 site of VcFur chain B. The 
maps represent a sigma-a weighted 2Fo-Fc map contoured at 1σ. The atomic 
model represents the final refined structure. W denotes water molecule. 
Table 5.2 Distances of Zn1 ligands in the crystal structure of VcFur 
Zn1, chain A Distance (Å) 
Zn- Nɛ2, His87 2.3 
Zn–Oδ2 Asp89 2.0 
Zn–Oɛ2 Glu108 2.1 
Zn–Nɛ2 His125 2.2 
  
Zn1, chain B Distance (Å) 
Zn- Nɛ2, His87 2.1 
Zn–Oδ2 Asp89 1.9 
Zn–Oɛ2 Glu108 2.1 
Zn–Nɛ2 His125 2.2 
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Figure 5.10 Metal binding ligands at Zn2 site of VcFur. Stereo view of the 
electron density around the zinc atoms in the Zn2 site of VcFur chain B. The 
maps represent a sigma-a weighted 2Fo-Fc map contoured at 1σ. The atomic 
model represents the final refined structure. 
Table 5.3 Distances of Zn2 ligands in the crystal structure of VcFur 
Zn2, chain A Distance (Å) 
Zn–Nɛ2 His33 2.1 
Zn–Oɛ2 Glu81 2.1 
Zn–Nɛ2 His88 2.1 
Zn–Nɛ2 His90 2.4 
  
Zn2, chain B Distance (Å) 
Zn–Nɛ2 His33 2.0 
Zn–Oɛ2 Glu81 2.1 
Zn–Nɛ2 His88 2.1 
Zn–Nɛ2 His90 2.2 
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6. Analysis of VcFur and discussion 
The VcFur structure is compared with the only other example of a Fur 
structure, Pseudomonas aeruginosa Fur. This reveals differences in metal 
binding coordination and the orientation of the DNA binding domain. Detailed 
structural comparison, metal content analysis and DNA binding studies of 
VcFur are presented in this chapter. EPR (Electron paramagnetic resonance 
spectroscopy) experiments of VcFur were designed to understand the 
movements of DNA binding domains in the presence of metal and DNA. 
Preliminary data from this experiment are also described in this chapter. 
6.1 Overall comparison with PaFur 
There is 50% sequence identity between VcFur and PaFur. The crystal 
structure of PaFur has a monomer in the asymmetric unit, the physiological 
dimer being generated by a crystallographic 2-fold axis. Superposition of the 
PaFur monomer with the A and B chains of VcFur gives an RMSD of 2.80 Å 
and 2.28 Å, respectively, reflecting the slightly different relative orientation of 
the DNA-binding domains in the VcFur dimer. A dramatically different 
orientation of the DNA-binding domains in VcFur compared to PaFur is 
revealed by superimposing the dimerization domains of a PaFur dimer onto 
the dimerization domains of the VcFur dimer (Figure 6.1). The structures of 
the individual domains of VcFur and PaFur are quite similar. The DNA-binding 
domains of VcFur (residues 3-82) and PaFur (residues 1-82) share 59% 
sequence identity and superimpose with an RMSD of 0.93 Å and 0.89 Å for 
chains A and B of VcFur, respectively (Figure 6.2). The dimerization domains 
of VcFur (residues 83-133) and PaFur (residues 83-135), which share 51% 
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sequence identity, superimpose with an RMSD of 1.12 Å and 1.07 Å for 
chains A and B of VcFur, respectively. 
The program LSQKAB in the CCP4 (CCP4., 1994) suite was used to compare 
the relative positions of the DNA-binding domains in the VcFur and PaFur 
dimers. In chain A of VcFur, an almost pure 32° rotation (the angle between 
the centroid vector and the rotation axis being 87°) relates this DNA-binding 
domain to that in PaFur. In chain B of VcFur, a more complex relationship 
exists involving a 24° rotation around an axis that is 74° to the centroid axis. It 
may be significant that in the VcFur crystal chain B has many more crystal 
contacts than chain A. As the individual domains are structurally very similar, 
the program DynDom (Hayward and Berendsen, 1998) was used to analyze 
the domain movement between VcFur and PaFur. This suggested that the 
bending region encompasses residues 82-88 of VcFur, with the DNA-binding 
domain rotating of 30° relative to the dimerization domain, in agreement with 
the LSQKAB analysis. The most significant consequence of the change in the 
orientation of the DNA-binding domains is the decrease in the distance 
between helix 4 of each DNA-binding domain. The geometry between the two 
helices 4 of the dimer was analyzed with the program INTERHELIX 
(http://nmr.uhnres.utoronto.ca/ikura/resources/resources.html). In the PaFur 
dimer, the two helices are 33 Å apart and oriented 86º to one another. In the 
VcFur dimer the equivalent helices are 25 Å apart and oriented 103º to one 
another. If dimers are constructed from the VcFur A or B chains 
superimposed by their dimerization domains, then a dimer formed from two A 
chains has the helices 27 Å apart, oriented by 102º. A dimer formed from two 
B chains has the helices 23 Å apart, oriented by 108º.  The change in 
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orientation is illustrated in Figure 6.1 by the change in distance between the 
Cα atoms of a conserved arginine on helix 4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1 Superposition of VcFur with PaFur structure. Orthogonal views of 
the superposition of the VcFur (green) and PaFur (cyan) dimers. The dotted 
lines indicate the distances between the Cα atoms of the conserved arginine 
(Arg57 in VcFur) on the DNA-recognition helix 4 (indicated as 4 in the picture). 
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Figure 6.2 Superposition of the DNA-binding domains of VcFur with PaFur. 
Monomer A of VcFur and PaFur are green and cyan in colour, respectively. 
6.2 Comparison of metal-binding sites of VcFur and PaFur 
In Figure 6.3 illustrates the metal binding sites of VcFur (chain A) compared 
with PaFur (chain A) following superposition of the two monomers via their 
dimerization domains. The coordination of Zn1 involves the same conserved 
residues (two histidines, a glutamic acid and an aspartic acid), but in VcFur 
the zinc is tetracoordinated whereas in PaFur the zinc is hexacoordinated 
through a bidentate interaction with Asp88 and by water molecule. In VcFur, 
the equivalent aspartic acid, Asp89, makes only a single interaction with the 
zinc, and although there is a water molecule in a similar position, it is 3.5 Å 
away from Zn1. The distance between the Zn1 zincs in the two structures is 
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0.5 Å, and the main difference in the coordinated side chains is the position of 
His87 (His86 in PaFur). The second metal binding site, Zn2, shows significant 
differences. The distance between the zincs in this site is 0.9 Å. In PaFur, no 
electron density was observed beyond Cβ for the side chain of His87. In 
contrast, the equivalent residue in VcFur, His88, is ordered in both monomers 
and coordinates to Zn2 in place of the glutamic acid Glu100 in PaFur. The 
closest carboxylate oxygen of Glu101, the equivalent residue in VcFur, is 
3.9 Å from Zn2. Comparison of PaFur with chain B of VcFur reveals a very 
similar picture, with minor changes around the Zn1 position and significant 
changes around Zn2, where the distance between the two zincs is 1.9 Å.  
 
 
 
 
 
 
 
 
 
Figure 6.3 A comparison of the metal binding sites of VcFur and PaFur 
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The metal binding sites of VcFur coloured by green whereas PaFur is 
coloured cyan. The residue numbers are shown for VcFur, with the residue 
number for PaFur in parentheses. For clarity, dotted lines indicate the 
coordination interactions of the zincs in VcFur only. Note that no electron 
density was observed in PaFur for sidechain atoms of His87 beyond the Cβ. 
6.3 Metal binding characteristics of VcFur 
An analysis of E. coli Fur (EcFur) showed that it contains 2.1 mol of Zn(II) per 
mol of EcFur monomer (designated as Zn2EcFur) when zinc was used in 
purification steps, and that one mol of Zn per monomer can easily be removed 
upon incubation/dialysis against EDTA (Althaus et al., 1999). Metals analysis 
results of native and EDTA treated VcFur samples are shown in Table 6.1. 
When zinc was used in the purification of VcFur, ICP-MS analysis revealed 
2.2 mol of Zn(II) per mol of Fur monomer (Zn2VcFur) and also 0.1 mol of 
nickel per mol of Fur monomer. When VcFur was purified without using zinc in 
the purification steps, there was 0.9 mol of Zn(II) per mol of Fur monomer 
(Zn1VcFur) and also 0.04 mol of nickel per mol of Fur monomer. The 
presence of nickel in VcFur indicates the purification of this protein through 
nickel column. In contrast to EcFur, when treated with EDTA, VcFur retains 
only 0.1 mol of Zn(II) per mol of VcFur monomer. 
The EDTA treated VcFur, containing almost no zinc, was dialysed with three 
different metals individually (Table 6.2). In reconstitution with Zn(II), 2.3 mol of 
zinc was incorporated per mol of VcFur, consistent with the previous amount 
of zinc found after purification of VcFur in the presence of zinc. In the case of 
Fe(III) reconstitution, 1.6 mol of iron was incorporated per mol of VcFur. In the 
case of Mn(II), 2.3 mol of manganese was incorporated per mol of VcFur 
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which is quite unusual as EcFur has little affinity for manganese (Mills and 
Marletta, 2005).  
Table 6.1 Metals analysis of native and EDTA treated VcFur samples 
Added Zn(II) 
used in 
purification 
EDTA Mol of Zn/ 
mol of 
VcFur* 
Mol of Ni/ mol of 
VcFur* 
Yes No 2.2±0.1 0.1±0.02 
Yes Yes 0.1±0.01 Not determineda 
No No 0.9±0.1 0.04±0.005 
No Yes 0.1±0.01 Not determineda 
* Averages from triplicate studies 
a  < 0.01 mol of metals per mol of VcFur monomer 
Table 6.2 Analysis of metal uptake into EDTA treated VcFur samples 
Mol of metals/ mol of Fur* Use of metals 
for reconstitution  
Zn(II) Fe(III) Mn(II) 
Zn(II) 2.3±0.1 Not determineda Not determineda 
Fe(III) 0.1±0.01 1.6±0.2 Not determineda 
Mn(II) 0.1±0.01 Not determineda 2.1±0.2 
* Averages from triplicate studies 
a  < 0.01 mol of metals per mol of VcFur monomer 
6.4 Mobility shift assay 
A DNA mobility shift assay was used to examine the interaction of VcFur with 
duplex DNA corresponding to the fur promoter of the gene vc2694 (Mey et al., 
2005). Zn1VcFur, that is the form containing one zinc per monomer, binds to 
the promoter (Figure 6.4.A). When MnSO4, ZnCl2 or FeCl3 was added to 
Zn1VcFur in the binding and running buffers, there was also a positive DNA 
mobility shift (Figure 6.4.B-D). When EDTA was used in the gel preparation 
and binding buffer with Zn1VcFur, no shift was found (Figure 6.4.E), 
suggesting that apo-VcFur does not bind to DNA. Upon adding metal salts to 
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the apo-VcFur (150 µM of ZnCl2, or 200 µM MnSO4, or 150 µM of FeCl3) in the 
binding and running buffer reaction, a mobility shift occurred (Figure 6.4.F-H). 
No shift was observed when non-promoter poly-A was used as a control 
(Figure 6.4.I). 
 
 
 
 
 
 
 
 
Figure 6.4 DNA mobility shift assays for VcFur. These assays show the effect 
of metals on the ability of VcFur to bind DNA. In each gel the rightmost lane is 
DNA alone. Upper bands (marked B) indicated protein-DNA binding, whereas 
lower bands (marked U) represent unbound fluorescent-labeled DNA. DNA 
concentrations were 50 nM. Protein concentrations decrease from left to right, 
and are indicated in nM  
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6.5 Electron paramagnetic resonance (EPR) spectroscopy of VcFur 
EPR spectroscopy provides different tools to examine the structure and 
structural changes of large biomolecules. Continuous wave and pulsed EPR 
can measure up to 80 Å by measuring the magnetic dipole coupling between 
two unpaired electrons (Schiemann and Prisner, 2007). EPR PELDOR 
(pulsed electron–electron double resonance) experiments can be used to 
identify conformational changes of VcFur DNA binding domain in the 
presence of different metals and DNA. There are a total of five cysteines 
present in VcFur (Cys31, Cys93, Cys96, Cys133 and Cys139 in Figure 5.1). 
We observed from the crystal structure of VcFur that there is a disulphide 
bond between Cys93 and Cys133, which has been described in Section 5.7 
and it is assumed that the Cys96 and Cys139 might also form a disulphide 
bond. So, Cys31 is the only free cysteine that can be spin labeled with MTSL. 
MTSL can attach to the free cysteine of the protein resulting in an increase in 
mass of 186.3 Da per spin label. The VcFur protein was spin labeled using 
the procedure described in section 2.24.6. ESI-TOF MS (electrospray-time of 
flight mass spectrometry) analysis shows that the native recombinant 
monomer of VcFur is 17,025 Da whereas the MTSL labeled monomer is 
17,210 Da. (Figure 6.5.A). Tryptic digested fragments of the VcFur protein 
were also analyzed and confirmed that the spin label was present at position 
Cys31 (Figure 6.5.B). As VcFur is a dimer and only one Cys31 in the DNA 
binding domain of each monomer can be labeled, any movements of the DNA 
binding domains due to metal coordination or formation of VcFur-DNA 
complex domain can be precisely measured by analysis of intensities 
generated by MTSL. These EPR experiments are currently underway. 
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Figure 6.5 Spin labeling of VcFur 
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(A) Recombinant VcFur monomer peaks from mass spectrometry data. (B) 
MTSL labeled VcFur monomer sample. Inset is an image of VcFur showing 
the location of Cys31 and the distance between the sulphur atoms observed 
in the crystal structure. 
 
 
 
 
 
 
 
Figure 6.6 Confirmation of Cys31 spin label in VcFur 
6.6 Discussion  
6.6.1 Structure and metal ligands of VcFur 
Given the key role of VcFur in the survival and pathogenesis of V. cholerae, 
we embarked on a structural investigation of VcFur with the ultimate aim of 
exploring the potential of developing an allosteric inhibitor of VcFur as a 
possible treatment for cholera. In this study, we present the crystal structure 
of VcFur to a resolution of 2.6 Å. An analysis of the metal binding 
characteristics of VcFur show that the protein can bind to promoter DNA in the 
presence of several divalent metals, and that the crystal structure contains 
two zincs per monomer. The residues coordinating the zincs are very similar 
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to those in PaFur, however the coordination details, particularly in Site 2, are 
different and this is possibly linked to a dramatic difference in the orientation 
of the DNA-binding domains relative to the dimerization domain. 
Recombinant VcFur, when purified without the addition of metal salts, 
contains essentially one zinc per monomer (0.9 mol of Zn(II) per mol of VcFur, 
(Table 6.1), and this form, Zn1VcFur, is able to bind to promoter DNA 
(Figure 6.4.A). The addition of Mn(II), Zn(II), or Fe(III) to the Zn1VcFur form 
maintains the ability of VcFur to bind to promoter DNA (Figure 6.4.B-D). Zinc 
can be removed from VcFur by EDTA treatment (0.1 mol of Zn(II) per mol of 
VcFur), and this form does not bind to promoter DNA (Figure 6.4.E). Adding 
back metals to EDTA-treated VcFur produces 2.3 mol of Zn(II), 1.6 mol of 
Fe(III) or 2.1 mol of Mn(II) per mol of VcFur (Table 6.2), and these forms are 
able to bind to promoter DNA (Figure 6.4.F-H). As reported for other Fur 
proteins, VcFur shares the ability to bind DNA in the presence of different 
metals (Bagg and Neilands, 1987; de Lorenzo et al., 1987). Analysis of metal 
binding to EcFur showed that in the presence of Zn(II) it contains 2.1 (Althaus 
et al., 1999) or 2.3 (Mills and Marletta, 2005) mol of Zn (II) per mol of EcFur, 
and that EDTA could remove one mol of zinc per monomer. Removal of all 
zinc from EcFur required urea treatment in addition to EDTA (Althaus et al., 
1999). EDTA treatment of VcFur resulted in 0.1 mol of Zn(II) per mol of VcFur, 
similar to the value of 0.19 mol reported for PaFur (Lewin et al., 2002). VcFur 
therefore contains two metal sites per monomer, and occupancy of at least 
one of these sites is necessary for DNA binding. The fact that Zn1VcFur can 
bind to DNA suggests that the single zinc per monomer is binding to the 
regulatory metal binding site, and that this is the high affinity site that requires 
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EDTA to remove the metal. Other divalent metals can bind at both sites and 
promote binding to DNA. 
The crystal structure of PaFur revealed the structural details of the metal 
binding sites for the first time for a member of the Fur family (Pohl et al., 
2003). It was suggested in the PaFur study that of the two zinc binding sites 
per monomer, the Zn(II) at site 1 (Zn1 in Figure 5.7.A and 5.11) is a low 
affinity metal binding regulatory site that can readily exchange iron causing a 
conformational change in the DNA binding domain of the protein, and that the 
Zn(II) at site 2 (Zn2 in Figure 5.7.A and 5.11) may be a structural metal 
binding site which helps to maintain the integrity of the protein (Pohl et al., 
2003). This interpretation has been challenged, based on an analysis of the 
reported mutagenesis of the ligands involved in binding the Zn(II) at site 2 in 
Fur from several species, and suggests that site 1 (Zn1) is the low affinity 
metal binding site with site 2 (Zn2) being the high affinity iron-sensing site 
(Lee and Helmann, 2007). This interpretation has been supported by a recent 
molecular dynamics and free energy calculation study of the binding of metals 
to PaFur that proposes site 2 as the regulatory iron-sensing site recognising a 
hexacoordinated Fe(II) in an octahedral environment (Ahmad et al., 
2008).This in silico study also suggested that His87 in PaFur might be an 
additional ligand of the metal at site 2. The structure of VcFur reported herein 
also reveals two metal binding sites per monomer, occupied by Zn(II). Zn1 at 
site 1 in VcFur is tetracoordinated by His87, Asp89, Glu108 and His125, 
residues that are conserved across all Fur proteins, including EcFur (Figure 
5.1). Although the corresponding residues in PaFur coordinate the Zn(II), the 
coordination involves six ligands achieved through a bidendate interaction 
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with Asp88 and by a coordinated water molecule. Zn2 at site 2 in VcFur is 
tetracoordinated to His33, Glu81, His88 and His90 in contrast to PaFur where 
His32, Glu80, His89 and Glu100 tetracoordinate the Zn(II). His87 in PaFur 
(the equivalent of His88 in VcFur) is disordered in the crystal structure of 
PaFur, but the fact that it is observed as a ligand to the Zn(II) in VcFur lends 
support to its involvement in coordinating Fe(II) at the regulatory site (Ahmad 
et al., 2008). Glu101 in VcFur (the equivalent of Glu100 in PaFur) is ordered, 
but too far away to coordinate to the Zn(II), however all five potential ligands 
His33, Glu81, His88, His90 and Glu101 are conserved across all Fur proteins 
and may therefore be involved in a hexacoordinated octahedral interaction 
with Fe(II). A His90Ala mutant of VcFur showed that His90 is critical for 
sensing iron (Lam et al., 1994), as have mutational studies of the same 
residue in Fur from other species (Bsat and Helmann, 1999; Hall and Foster, 
1996; Lewin et al., 2002). Mutational studies on Vibrio alginolyticus Fur, which 
shares 94% sequence identity to VcFur, shows that mutation of His33 or 
His90, ligands of Zn2, completely inactivates Fur, whereas mutation of His87 
and His125, ligands of Zn1, resulted in just a 2-fold reduction of Fur activity 
(Liu et al., 2007). It can be concluded that site 1 (Zn1) plays a structural role 
and is not critical for activity, and site 2 (Zn2) is the regulatory site. A study of 
EcFur concluded that in vivo zinc concentrations are too low for Zn(II) to be a 
regulatory ligand, and that Fe(II) is the physiologically-relevant ligand that 
activtes Fur (Mills and Marletta, 2005). This is also likely to be the case for 
VcFur, but Mn(II) may also be a ligand given its ability to occupy both metal 
binding sites and activate DNA binding, however an analysis of metal 
concentrations in V. cholerae would be needed to confirm this.  
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There have been many reports, based on a study of EcFur, that four cysteines 
(Cys92, Cys95, Cys132, Cys137, in EcFur numbering) conserved throughout 
most of the Fur family are involved in coordination of zinc (Jacquamet et al., 
1998), specifically the Cys92XXCys95 motif (Coy et al., 1994; Gonzalez de 
Peredo et al., 1999), and that the redox state of these cysteines and 
coordination of zinc are essential for maintaining EcFur in a dimeric state 
(D'Autreaux et al., 2007). PaFur appeared to be an exception as the second 
cysteine of this motif is a threonine (Figure 5.1). Despite having the conserved 
cysteines the structure of VcFur presented here does not reveal any metal 
binding site involving the cysteines, but shows that there is a disulphide 
linkage between Cys93 and Cys133 (equivalent to Cys92 and Cys132 in 
EcFur), in conflict with the disulphide analysis of the monomer to dimer 
transition of EcFur (D'Autreaux et al., 2007). It may be that this disulphide 
observed in VcFur would not form in the reducing environment of the cell. In 
the VcFur structure there is no electron density beyond Cys133, although 
mass spectrometry analysis confirms that the C-terminal residues are present 
in the crystal. The similarity between EcFur and VcFur in the number of 
metals bound per monomer, and the observation that the two zinc binding 
sites are conserved in the crystal structures of PaFur and VcFur, involving 
residues conserved across all Fur proteins, suggests that EcFur may also 
share the same two metal binding sites. How this squares with the reports on 
zinc binding to the conserved cysteines in EcFur is difficult to explain, 
although there is report that the cysteines in EcFur do not bind zinc (Saito et 
al., 1991).  Perhaps family members have subtle variations in metal binding 
sites that maintain structural integrity rather than regulatory roles.  
 156 
6.6.2 DNA-binding model 
Comparison of the crystal structures of VcFur and PaFur reveals a significant 
shift in the position of the DNA-binding domain relative to the dimerization 
domain, such that the mid-point distance between helix 4 in the dimer reduces 
from 33 Å in PaFur to between 23 and 27 Å in VcFur. For example the 
distance between the two Cα atoms of the conserved tyrosine in helix 4 of the 
dimer (Tyr55 in PaFur, Tyr56 in VcFur), that has been implicated in DNA 
recognition of the Fur-box (Tiss et al., 2005), is 31 Å in PaFur and 21 Å in the 
VcFur. The consensus Fur-box sequences of E. coli, P. aeruginosa and 
V. cholerae are very similar: 5'- GATAATGATAATCATTATC -3', 5'-
GATAATGATAATCATTATC -3' and 5'- GATAATGATAATNATTATC -3', 
respectively (de Lorenzo et al., 1987; Mey et al., 2005; Ochsner and Vasil, 
1996). Although the Fur-box sequence is an inverted repeat sequence, there 
is extensive evidence that more than one Fur dimer binds to the Fur-box. One 
study described the Fur-box as a head-to-head-to-tail repeat of the simple 
hexamer GATAAT and proposed that this hexamer is the minimal recognition 
unit for Fur (Escolar et al., 1998), and that longer operator regions can be 
formed by simple repeats of the hexamer (Escolar et al., 2000). An alternative 
view of the Fur-box is that it contains a conserved 15-bp (7-1-7) inverted 
repeat presented twice within the 19-bp consensus sequence (Figure 6.7) 
(Baichoo and Helmann, 2002). This study showed that the stoichiometry of 
binding was one Fur dimer per 15-bp inverted repeat, and two Fur dimers per 
19-bp Fur box, with each 7-1-7 inverted repeat predicted to bind a Fur dimer 
on opposite sides of the DNA. Such a model of binding was proposed for 
PaFur (Pohl et al., 2003). The diptheria toxin repressor (DtxR) operator 
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sequence has been described as two similar 7-0-7 inverted repeats, and 
structural studies on DtxR binding to DNA shows two DtxR dimers binding to 
these repeats on either side of the DNA duplex (Figure 6.7) (Pohl et al., 1999; 
White et al., 1998).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.7 Comparison of possible Fur-DNA complex with the DtxR-DNA. 
Adapted from Baichoo et. al. (Baichoo and Helmann, 2002). (A) 19-bp Fur 
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box binding site with two overlapping 7-1-7 heptamer motifs. (B) Two 
overlapping imperfect inverted repeats that generate the 19-bp binding site for 
DtxR (Chen et al., 2000). (C) DtxR-DNA complex (PDB code 1ddn) involves 
two dimers of DtxR bound to the operator DNA. 
This study, when combined with the PaFur study, has shown that there is 
flexibility of the DNA-binding domains relative to the dimerization domain, with 
the distance between the two key DNA-binding helices (helix 4) varying from 
23 Å to 33 Å. It could be envisaged that one particular form may be better 
stabilized through the hexacoordination of Fe(II) at site 2 (Zn2) involving the 
five conserved residues His33, Glu81, His88, His90 and Glu101 (VcFur 
numbering) with one of the glutamic acid residues forming a bidentate 
interaction, and this is supported by the recent molecular modeling studies 
(Ahmad et al., 2008). In both the PaFur and VcFur structures zinc is only seen 
to form tetracoordination at site 2 with the consequence that in VcFur the 
DNA-binding domains are not in an optimal position for DNA-binding. Clearly 
the Zn(II) form can bind to promoter DNA, but the conformational changes 
required for association with DNA would provide an energetic penalty that 
would reduce the binding affinity in line with the reduced affinity seen for Zn(II) 
EcFur compared to Fe(II) EcFur (Mills and Marletta, 2005).  
In conclusion, these studies on VcFur support the hypothesis that site 2 is the 
regulatory site where Fe(II), or possibly Mn(II), binds to control repression 
in vivo. The variation in the position of the DNA-binding domains compared to 
that observed in PaFur suggests that Zn(II) binding at site 2 (Zn2) may not 
lock the DNA-binding domains in the optimal position for DNA binding. The 
combined structural studies suggest that Fe(II) binding to site 2 would employ 
 159 
five conserved residues to form a hexacoordinated interaction rather than the 
tetracoordinated interaction seen with Zn(II), and that these additional ligands 
would help generate the optimal orientation of the DNA-binding domains. A 
more complete understanding still awaits the elucidation of a Fur-DNA 
complex, ideally in the presence of iron, but these studies on VcFur provide 
further insights into this important family of gene activators and repressors. 
6.7 Ongoing and future work 
The structure of VcFur will definitely improve our understanding of this highly 
conserved metalloregulatory transcriptional factor. However, the structure 
resolution needs to be improved to better understand metal co-ordination of 
VcFur. As the bacterial cell cytoplasm is always in a reduced condition, the 
presence of disulfide bridges between cysteine residues Cys93 and Cys133, 
and between Cys96 and Cys139 in VcFur is questionable in vivo. Purified 
VcFur protein in the absence of DTT contains disulphide linkages, consistent 
with the results of spin labeling (Section 6.5). Further biochemical 
characterization of the protein with regard to the oxidation state of the 
cysteines, the oligomeric state of the protein as a function of this redox state 
and of the metal binding are underway. Improvements in mobility shift assay, 
by using gel purified double stranded DNA, are also in progress. Microcrystals 
of VcFur-DNA complex were observed in certain crystallization conditions and 
further optimizations are in progress. To investigate DNA binding domain 
movements of VcFur in the presence of different metals and DNA, electron 
paramagnetic resonance (EPR) experiments are underway in the University of 
St Andrews. 
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In V. cholerae, more than 100 genes can be regulated by VcFur and fur gene 
knockout strain showed significant reduction in virulence (Mey et al., 2005). 
Structural investigation and functional characterization of VcFur was carried 
out to design a potential inhibitor. Future approaches should aim to design a 
small molecule inhibitor to keep VcFur as an inactive form either by blocking 
the DNA or metal ligand binding sites. Equally, upregulation of VcFur could 
potentially block the expression of many genes involved in maintaining iron 
homeostasis in V. cholerae. Hence, another approach could be to design an 
allosteric activator to keep VcFur constitutively active. Future experiments will 
involve identification of lead compounds using fragment based screening, 
thermal shift assay, computer analysis, crystallography, synthetic chemistry 
and biochemical assay. 
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